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1. Introduction  
1.1. Overview on idiopathic pulmonary fibrosis 
Idiopathic pulmonary fibrosis (IPF) is a chronic, devastating, and lethal fibrotic disorder in 
human lung, known also as cryptogenic fibrosing alveolitis, with a reported median survival 
of 3 to 6 yr, its incidence continues to rise and the prognosis is even worse than in many 
cancers [1-4]. IPF lung specimens show different histological patterns and the usual 
interstitial pneumonia (UIP) is seen in the majority of patients, where this terminology was 
also used as synonym [1] (Fig.3).  IPF is characterized by a worsening of pulmonary function, 
and persistent alterations of the lung parenchyma because of fibrotic foci formation by 
activated fibroblasts and myofibroblasts and excessive production and deposition of 
extracellular matrix components (ECM) [5-8] (Fig.1). In the lung of IPF patients, an increase 
in relative number of myofibroblasts to fibroblasts is present along with the formation of 
fibroblastic foci with progressive deposition of abundant extracellular matrix in the interstitial 
tissue of the alveolar region [2, 8]. Several factors were thought to influence and initiate this 
lung disease, such as free radicals generated in the microenvironment of the alveolar region, 
smoking, pollution, general infections and to some extent also unknown genetic factors, 
leading to the ultimate death of patients (Fig.1). To date not a single factor could be identified 
solely causing this devastating disease [8]. IPF differs from other usual interstitial pneumonias 
in containing low antioxidant levels and having a poor prognosis. The correct diagnosis of IPF 
is difficult, since it exhibits similarities in physiology, clinical and pathological conditions 
with other interstitial lung diseases [9]. However, the histology of IPF in lung samples is 
characterized by the typical interstitial fibrosis and the honey comb like structure in end stage 
IPF samples, distinguishing IPF from other diseases with interstitial pneumonia [9].    
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Fig 1. Mechanism involved in idiopathic pulmonary fibrosis [2]. 
 
Lung fibrosis in IPF begins in subpleural areas with fibroblast proliferation, alveolar epithelial 
atypia and spreads centrally later with time forming  honeycombing structures as a marker of 
advanced lung fibrosis in fibrotic regions of the IPF lung [10](Fig.2).  Inflammation in IPF is 
relatively low if compared to other interstitial lung diseases with high abundance of 
neutrophils and lymphocytes. Moreover, immature fibrotic regions with active 
myofibroblastic foci are more prone to extracellular matrix production in IPF [10] (Fig. 1, 2).  
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Fig 2. High resolution computerized tomography (HRCT), subpleural honeycombing (left), subpleural 
fibroblast proliferation and epithelial atypia right). Alpha-actin positive cells show red staining in 
photomicrographs (200× magnification) [10]. 
 
Furthermore, chronic inflammation is assumed to be the key factor in IPF with inflammatory 
mediators such as chemokines, cytokines, growth factors, and reactive oxygen species being 
discussed as key players in the progression of this disease [3].  In addition, it is shown in this 
thesis that TNF- seems to play an important role in initiation and perpetuation of the fibrotic 
processes via AP-1signaling pathway [11]. It is well accepted that TGF- signaling plays a 
critical role in IPF development. Inhibition of TGF- signaling by blocking its downstream 
Smad3 gene expression protects against bleomycin induced fibrosis in animal models [12, 
13]. However, the mechanisms by which TGF- and TNF- promote the fibrotic response in 
IPF are incompletely understood.  
 
 
 
 
 
 
 
 
Fig. 3. Histopathological appearance: fibrotic foci in idiopathic pulmonary fibrosis [2]. 
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1.2. The pathogenesis of idiopathic pulmonary fibrosis 
The pathogenesis of idiopathic pulmonary fibrosis is a very complex process, there is no 
unifying mechanism that explains the complete lung fibrogenesis and most likely it is a 
multifactorial process [14]. The current hypotheses suggest that two different cellular 
mechanisms exist, 1) the inflammatory pathway and 2) the epithelial pathway, which could 
lead to development of lung fibrosis [2, 15, 16]. As a key process are suggested the multiple 
subclinical injuries to the lung with epithelial damage and subsequent alveolar basement 
membrane destruction [17]. This damage exerts a deteriorating process with fibrogenic cell 
infiltration, generation of myofibroblasts from fibroblasts exhibiting the expression of alpha 
smooth muscle actin (SMA), and subsequent ECM production [17, 18]. An essential role in 
the pathogenesis of IPF plays the TGF- signal transduction pathway resulting in increased 
ECM and collagen production [19]. The Smad3 knockout mice, deficient in a downstream 
mediator of TGF- signaling, were shown to be protected from bleomycin-induced 
pulmonary fibrosis [13]. According to one theory, the increase of oxidants or a toxic event 
might lead to the destruction of the alveolar epithelium and its basement membrane, inducing 
hyperplasia of fibroblasts and a reactive synthesis of extracellular matrix in the underlying 
region of the connective tissue [20]. Several inflammatory mediators such as cytokines, 
chemokines, growth factors and reactive oxygen species (ROS) are implicated in the 
pathogenesis of IPF [20]. Furthermore, the WISP1 protein localized in alveolar type II cells 
(AECII), a downstream molecule of WNT signaling is involved in pulmonary fibrosis. Its 
depletion attenuates the bleomycin induced lung fibrosis in vivo, while WISP1 treatment 
increased ECM production and epithelial mesenchymal transition (EMT) [21, 22]. Moreover, 
the phosphotase and tensin homologue (PTEN) seems to be a crucial protective factor in the 
pathogenesis of many non-malignant diseases such as rheumathoid arthritis, asthma and 
pulmonary fibrosis. The expression of PTEN in patients with IPF was found to be 
downregulated in myofibroblasts with fibroblastic foci [23, 24]. The exact contribution of 
each process in the pathogenesis of IPF is incompletely understood. In the bleomycin lung 
fibrosis mouse model, one third of lung fibroblasts derive from the lung epithelium two weeks 
after bleomycin treatment, and bone marrow accounts for one fifth of fibroblasts, but only a 
minority of cells are SMA+ myofibroblasts and just a few of these cells seem to derive 
from EMT [25]. Possibly, bleomycin accelerates the conversion of the AECII into AECI cells, 
and different cell types proliferate in the fibrotic lesions and exclude the epithelial cell 
populations and pericytes as the origin of lung myofibroblasts [26].  
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1.3. Overview on treatment approaches for IPF 
As mentioned above, IPF is characterized by a continuous decline in pulmonary function that 
mainly leads to respiratory failure and death, and to date its therapeutic approaches are very 
limited [2]. The treatment approach for acute exacerbations of IPF used to consist of high 
doses of corticosteroids, even though there are no data from controlled trials to prove their 
efficacy in IPF patients [27, 28]. However, a beneficial effect of anticoagulant therapy on the 
overall survival, but not on clinical condition improvement of IPF patients was demonstrated 
[27]. In addition, there is also no convincing evidence shown to prove cyclosporine A as 
beneficial in treatment of acute exacerbations [28, 29]. Data from randomized clinical trials 
suggest a possible role and benefit of patients with IPF from sildenafil, as secondary outcome 
including relieve of dyspnoea and improving the quality of life, by optimizing the ventilation-
perfusion matching in patients with pulmonary fibrosis [30]. Also, treatment of IPF patients 
with bosentan, an endothelin receptor antagonist, was not superior to placebo and no changes 
from baseline were observed within one year, by measuring the quality of life or dyspnoea 
[2]. Importantly, a study from a randomized phase III clinical trial demonstrated pirfenidone, 
an inhibitor of both production and activity of TGF- as a promising agent, with a therapeutic 
potential for treatment of IPF [31]. This drug possesses combined anti-inflammatory, anti-
oxidant and anti-fibrotic properties, which preserves vital capacity (VC) and improves 
progressive free survival (PFS) better than placebo in patients with IPF in Japan [31]. 
Moreover, Nintedanib an intracellular inhibitor that targets multiple tyrosine kinases was 
shown to slow the disease progression and FVC decline in patients with idiopathic pulmonary 
fibrosis [32]. In addition, in a mouse model of bleomycin-induced pulmonary fibrosis in mice, 
TNF-alpha antagonists inhibit inflammation and fibrosis development [33], indicating a 
possible beneficial function in diminishing the fibrotic response in patients with IPF. 
However, etanercept, a TNF-alpha antagonist, used as treatment for IPF in a clinical study 
revealed no differences in the predefined endpoints among patients with IPF who received the 
drug or placebo [34]. A clinical trial from Demedts and colleagues demonstrated that the 
acetylcysteine added to prednisone and azathioprine therapy in patients with IPF maintains 
the vital capacity and Dlco (diffusing capacity of the lung for carbon monoxide) better than 
solely standard therapy [35]. Transplantation of prominin-1/CD133 positive epithelial 
progenitor cells (PEPs) in bleomycin-induced lung fibrosis mice suppressed proinflammatory 
and profibrotic response and protected mice from bleomycin-induced pulmonary fibrosis [36, 
37]. Lung transplantation is considered as final treatment approach in patients with end-stage 
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of IPF. Mostly, a bilateral rather than a single lung transplantation is taken into consideration 
[38].  
 
1.4. TGF-β signaling in the promotion of fibrosis 
TGF-1 is a growth factor produced by several cell types, and the most studied cytokine 
critical in pathogenesis and development of IPF with variable functions in cell differentiation, 
proliferation, apoptosis and cancerogenesis [39, 40]. Initial microinjuries and cell damage to 
the alveolar epithelium trigger the production of the fibrogenic mediator TGF- by 
inflammatory and epithelial cells, which in turn induces the synthesis of extracellular matrix 
proteins and inhibits collagen degradation by activation of protease inhibitors and MMPs [40, 
41].  In mammals, three variant isoforms of the TGF- family exist: TGF-, -2, and -3 [42], 
from which TGF-is most related to the development of IPF [39]. This cytokine is first 
secreted in an inactivated form, in a complex of latent TGF- bound to the latency associated 
protein (LAP) and latent TGF--binding protein (LTBP) (Fig. 4).  
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Fig.4. The  mechanisms of extracellular activation and intracellular signaling of TGF- on the expression 
of the TGF-, proCOL1A1, proCOL1A2, and Smad 7 genes. Synthesis and post translation hydroxylation 
modification of proCOL1A1, proCOL1A2 polypeptides, collagen triple helix formation, and propeptide globular 
extension formation [43]. 
 
The active TGF- release from the LAP/LTBP complex can be mediated by matrix 
metalloproteinases (e.g. MMP2 and MMP9), tissue stiffness, by reactive oxygen species, 
acidic pH changes, thrombospondin-1 and integrins V3, V5, V8, V6, which have 
been demonstrated to play a critical role in TGF- activation and the fibrotic response [40, 
44-48]. Active TGF- binds to two types of receptor serine/threonine kinases, type I and 
type II [49]. Activation of TGF- leads to phosphorylation and activation of the TGF-
receptor type I by the type II receptor, inducing the activation of the Smad signaling 
pathway by phosphorylating Smad transcription factors such as Smad2 and 3, which shuttle to 
the nucleus and form a complex with Smad4 [49, 50] (Fig. 4).  
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1.5. Extracellular matrix (ECM) components in fibrosis  
1.5.1. Collagen and fibronectin   
Abnormal collagen production/deposition is a major feature of pulmonary fibrosis. In the late 
1980s, it has been suggested that all types of collagen are produced after the TGF- 
stimulation, and that fibroblasts from both normal and fibrotic human lungs would synthesize 
the same amounts of collagens [51]. Distribution of collagens is variable, type I collagen is 
localized to the interstitium of alveolar septa, type III is more prominent and has irregular 
perivascular and septal localization, while type IV is present in alveolar and capillary 
basement membranes [52]. Superoxide anions are inducing collagen type I degradation via 
activation of neutrophiles and release of collagenases [53]. Furthermore, as mentioned before 
epithelial injury and deterioration of the alveolar basement membrane (comprised of type IV 
collagen) are known to contribute to the pathogenesis of lung fibrosis [10, 54]. Fibronectin is 
a glycoprotein and an abundant compound of the ECM. It is comprised of N-terminal 70 kDa 
domain, the central binding domain 120 kDa, and the heparin-binding domain HepII4 [55]. 
These domains interact with cell-surface receptors and bind to integrin- and heparin sulphate 
proteoglycan (HSPG) cell-surface receptors, which trigger the reorganization of actin 
cytoskeleton [55].  TGF-1 activity induces the alternative splicing and the increase of the 
fibronectin gene expression [55, 56]. Moreover, fibronectin (Fn) participates in the activation 
of latent TGF- by V6 integrins on epithelial cells,, upon binding to the latent TGF- 
binding protein (LTBP-1), and deletion of fibronectin fails to activate TGF- [55]. TGF- 
as key mediator in ECM regulation stimulates the expression and secretion of different ECM 
proteins, such as fibronectin, thrombospondin, tenascin and vitronectin [55, 57]. Fibronectin 
receptors are critical for the induction of TGF- and thereby myofibroblast differentiation 
[58].  
 
1.5.2. Fibroblasts and myofibroblasts in IPF 
Fibroblasts are mesenchymal cells, very abundant in the loose connective tissue. They play a 
critical role in ECM production, remodeling and wound repair [59, 60]. Various studies have 
proposed circulating fibrocytes, epithelial derived fibroblasts, resident fibroblasts and 
pericytes as main source of lung myofibroblasts [26, 61]. Proliferation rate is higher in human 
lung fibroblasts derived from fibrotic lung tissue compared with the normal lung, and the 
highest proliferation rate was found in fibroblasts obtained from areas with early fibrosis 
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compared with normal lung areas, whereas proliferation rate is obviously reduced in cells 
obtained from dense fibrotic tissue [51, 62]. Furthermore, fibroblasts are a very heterogeneous 
population, with phenotypic diversity, difference in surface markers, cytoskeletal structure 
and cytokine release [62, 63]. Myofibroblasts as unique subpopulation of fibroblasts are the 
main source of ECM production, express smooth muscle features, and are responsible for 
collagen accumulation [62, 64, 65]. TGF- is the key cytokine of fibroblast-myofibroblast 
differentiation provoking such effects via the Smad-dependent signal transduction pathway, 
including proliferation, migration, chemoattraction of inflammatory cells and tissue repair 
[66, 67]. A characteristic difference between the two cell types “fibroblasts versus 
myofibroblasts” is the resistance of myofibroblasts to apoptosis, a property similar to 
malignant cells, which may lead to abnormal wound healing or contractive tissue repair 
processes, leading to fibrogenesis [68]. In addition, myofibroblasts release ROS and are under 
oxidative stress, a major factor contributing to apoptosis [47]. In IPF, the apoptotic process 
seems to be impaired, resulting in over production of ROS, cytokine release and epithelial cell 
injury [19, 47].  
 
1.6. TGF-role in myofibroblast differentiation and ECM regulation 
Differentiation of fibroblasts into myofibroblasts is another proinvasive feature of TGF. 
These myofibroblasts secrete excessive TGF-, which provokes ATII cell apoptosis, hereby 
deteriorating the wound healing process [40, 43] (Fig. 5).  Lung fibroblasts are key cells for 
synthesizing collagen and generation of ECM, and TGF- is the “master switch” for the 
pulmonary fibrosis [19, 69]. The collagen type I was the major type synthesized by both 
normal and fibrotic cell types, whereas TGF-beta induces the synthesis of different collagen 
types such as I, III, and V in fibroblasts and myofibroblasts [51, 70]. TGF-	Smad signaling 
enhances the transcriptional activation of collagens, as consequence myofibroblasts express 
high levels of ECM especially collagens and fibronectin, contributing to the deposition of 
collagens and fibrosis [40, 43]. 
 
10 
 
 
Fig. 5. Role of TGF in idiopathic pulmonary fibrosis (IPF) pathogenesis. Multiple presumed microinjuries 
to the alveolar epithelium induce the apoptosis of alveolar type I (ATI) and alveolar type II (ATII) cells, basal 
membrane disruption, and TGF production in macrophages, epithelial cells, or activated myofibroblasts. This 
condition  perpetuates the aberrant wound healing process by inducing extracellular matrix production, 
promoting myofibroblast recruitment and activation from resident lung fibroblasts, epithelial mesenchymal 
transition (EMT) or endothelial mesenchymal transition (EndoMT), bone-marrow derived fibrocytes, or 
pericytes from the surrounding vessels and interstitium [40]. 
 
1.7. TGF- in induction of epithelial-mesenchymal transition (EMT) 
Fibroblast heterogeneity isolated from IPF lungs suggests that fibroblasts are derived from 
multiple cell types [71]. Kim and colleagues found that IPF lungs have acquired mesenchymal 
features from epithelial cells, and that this process is triggered by activation of the integrin 
V6 and subsequently TGF-1 activation, suggesting the implication of the EMT process 
during fibrogenesis [71]. The complete mechanism of EMT remains to be explained. TGF-1 
11 
 
signaling through Smad specific proteins, as well as various other downstream kinases, 
including mitogen-activated protein kinase (MAPK), Rho kinase, Rac1, integrin linked 
kinase, etc. Which are Smad-independent pathways [72-74].  
 
1.8. Matrix metalloproteinases in abnormal lung remodelling in IPF 
MMPs are critical in would repair and in tissue remodelling [75]. They can activate growth 
factors such as TGF-1 and other cytokines and play an important role in various diseases as 
arthritis and fibrosis [75, 76]. Various metalloproteinases such as MMP-1, MMP-2 and MMP-
9 were found to be upregulated in human pulmonary fibrosis and animal models of pulmonary 
fibrosis [22, 77, 78]. In addition, an increased MMP-7 was also reported in usual interstitial 
pneumonia (UIP), a histological description for fibroblastic foci [79]. Consistently, MMP-7 
knockout mice were protected from bleomycin-induced pulmonary fibrosis [79], suggesting 
that inhibition of MMP-7 may be used as therapeutic tool in this chronic deteriorating disease 
[79]. Furthermore, MMP-3 is found to be directly involved in the epithelial-mesenchymal 
transition, a pivotal process in pathogenesis of fibrosis and neoplasia [76], and genetic 
abrogation of MMP-3 protects the mice from bleomycin-induced lung fibrosis [75].  
 
1.9. TGF-1 and reactive oxygen species in the pathogenesis of IPF 
1.9.1. Role of TGF-1 and ROS generation  
Human lungs are permanently exposed to higher concentrations of oxygen compared to other 
organs. Therefore, alveolar epithelial cells are more prone to oxidative injury [5, 80]. Reactive 
oxygen species (ROS), such as superoxide anions (O2-.), hydrogen peroxide (H2O2), and 
hydroxyl radical (OH.) regulate cell signaling in physiological conditions, but an excess of 
reactive oxygen species leads to organ injury [81]. ROS can damage alveolar epithelias cells, 
such as DNA, proteins and lipids. Many studies suggest that the imbalance between oxidants 
and antioxidants could play a major role in development of lung fibrosis [45, 58]. For 
example, TGF-1 triggers extracellular secretion of H2O2 in lung fibroblasts in humans, by 
activating NADH:flavin:O2 oxidoreductase [82],  while ROS play an important role in 
induction of TGF-1 signaling, leading in consequence to collagen-I synthesis and 
fibrogenesis in pulmonary fibrosis [45, 83, 84]. ROS are critical components involved in 
fibrotic process, shown in IPF patients and bleomycin-induced pulmonary fibrosis in animal. 
Absence of ROS in mice with deficiency for the p47phox subunit of NADPH-oxidase (Nox) 
12 
 
protects the mice against bleomycin induced lung fibrosis [83, 85]. NOX4-dependent 
generation of H2O2 is also crucial for TGF-β1-induced myofibroblast differentiation and ECM 
production [86]. Upregulation of NOX-4 is found in human idiopathic pulmonary fibrosis and 
in the mouse lungs subjected to non-infectious injury [86]. Moreover, superoxide dismutases 
(SODs), such as SOD1 (CuZnSOD), SOD2 (MnSOD), and SOD3 (ECSOD), are known to 
reduce oxidative stress by catalyzing the dismutation of superoxide into oxygen and hydrogen 
peroxide [58]. Deletion of ECSOD in mice aggravates the pulmonary damage after exposure 
to bleomycin or asbestos [87]. 
 
 1.9.2. Fibrogenesis induced by oxidative stress  
In the literature, it was speculated that direct injury to the alveolar epithelium and the 
inflammation in the alveolar and bronchiolar regions could induce the activation of signaling 
pathways, that lead to the elevated expression of proinflammatory genes in fibroblasts, and to 
the release of profibrotic cytokines (TGF-β1, TNF-alpha, IL-1, IL-6, IL-8), growth factors 
such as PDGF and chemokines [58, 88]. Besides proliferation of myofibroblasts in IPF lungs, 
cytokine-mediated ROS release can lead to apoptosis of type I alveolar epithelial cells, with 
subsequent exposure of the basement membrane and the ECM production leading to the 
activation of alveolar macrophages [45].  Elevation of ROS production via activation of 
immune cells such as macrophages, neutrophils through NADPH oxidase activation is also 
noted in IPF patients [88]. Furthermore, also imbalance of MMPs and TIMPs (tissue inhibitor 
of matrix metalloproteinases) might trigger ROS or RNS alterations, generating the 
overdeposition of secreted extracellular matrix material [88, 89] (Fig.6). TGF- activation by 
ROS is specific for the TGF- isoform and the methionine residue 253 in the TGF-1/LAP 
complex is important and functions as redox switch center [90]. In addition, the oxidation of 
LAP was always paralleled by increased levels of HO-1, this was implicated later in releasing 
the mature TGF-1 [91] (Fig.6). Induced activation of TGF-by increased ROS and 
apoptosis was also demonstrated in peroxiredoxin 6 knockout mice (Prdx6) [92].  
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Fig. 6. Activation of latent TGF- complexes  by ROS- MMPs and integrins [90]. 
 
 1.10. AP-1 signaling in idiopathic pulmonary fibrosis 
The transcription factor activator protein 1 (AP-1) is a dimeric molecule composed of 
members of the Jun (c-Jun, JunB, and JunD), Fos (c-Fos, FosB, Fra-1, and Fra-2) and ATF 
families of proteins [93, 94]. C-Jun is involved in regulation of cell proliferation and 
fibroblasts deficient in c-Jun exhibit reduced proliferation due to a cell cycle defect as well as 
an increase of the tumour suppressor genes p53 and p21 [95, 96]. AP-1 family members are 
implicated in different stress signals and control subsequent processes including proliferation, 
apoptosis, wound healing, inflammation, tumourigenesis [97, 98]. In particular, Fra-2 and 
JunD are involved in regulation of ECM synthesis and aberrant activation of fibroblasts [98]. 
These effects have made AP-1 a potential candidate for antifibrotic therapy [97, 98].  
Furthermore, inhibition of AP-1 abrogated the profibrotic effects of TGF signaling and in 
consequence prevented the development of skin fibrosis in one mouse model of SSc (systemic 
sclerosis), also called bleomycin-induced dermal fibrosis [97]. Therefore, this approach might 
become a promising therapy for treatment of fibrotic disorders [97]. Similar beneficial effects 
of AP-1 inhibition in preventing ECM generation and TGF-1 signaling activation were also 
noted in Swiss 3T3 fibroblasts treated with TNF-alpha [99].  
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1.11. Inflammation and implication of cytokines (TNF-alpha and IL-6) in 
pulmonary fibrosis  
Cytokine release has been one of the major critical factors leading to the fibrogenesis 
observed in the bleomycin-induced lung fibrosis mouse model. In particular TNF-alpha plays 
an essential role for the development of the BLM-induced lung injury, partially through 
upregulation of TGF- expression [100, 101]. TNF-alpha is produced by many cell types 
upon injury or infection, which may participate in cell proliferation, differentiation or 
apoptosis [102]. The use of TNF-alpha antagonists, was effective not only in abrogating the 
development of lung fibrosis but also reduced an established fibrosis in bleomycin or silica 
instillation-induced mouse lung fibrosis models [33]. An increased expression of -SMA and 
COL1 protein was also noted in recombinant human TNF- treatment (rhTNF-) of palmar 
fibroblasts in Dupuytren´s disease [101]. In addition, TNF-alpha increases TGF-1 expression 
and enhances ECM synthesis in the Swiss 3T3 fibroblasts [99]. IL-6 cytokine is secreted by 
various cell types (including fibroblasts), and mediates inflammatory processes in the lung in 
a variety of disease situations including interstitial lung diseases [103]. Moreover, the role of 
IL-6 in the lung inflammation was further analyzed by treating wild-type and IL-6-deficient 
mice with bleomycin [104]. In comparison to WT-mice, the IL-6 deficient mice expressed 
lower numbers of macrophages, total cells and neutrophils in the bronchoalveolar lavage 
(BAL) [104]. Taken together, these studies indicate that inhibition of TNF-alpha or IL-6 
release plays an important role in preventing and/or attenuating BLM-induced lung fibrosis, 
which may be a potential therapeutic approach in treating pulmonary fibrosis [103, 104].  
 
1.12. TGF-beta receptor II kockout mice are protected from pulmonary 
fibrosis 
Increased expression and activation of TGF- have been demonstrated in IPF patients as well 
as in experimental models of pulmonary fibrosis [105, 106]. The activated TGF- can bind to 
the serine/threonine kinase receptors, TGF- receptor II and I complex (TRII and TRI) and 
lead to phosphorylation of downstream intracellular molecules such as Smad2/3 and 
subsequently gene expression [40, 105]. Recently, it was reported that the abrogation of the 
TGF- signaling in lung resident mesenchymal cells, using a Tbx4 lung enhancer-driven Tet-
On transgenic system to delete TGF- receptor II or express dominant-negative TGF- 
receptor II, has significantly inhibited the BLM-induced fibrotic response [105, 107].  In 
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addition, the blockade of TGF- receptor type II in epithelium decreases epithelial 
permeability, preserves lung function and thus protects mice from bleomycin induced lung 
injury and pulmonary fibrosis [106]. Furthermore, the peroxisome is downregulated in BLM-
induced wild type mouse lung fibrosis, which can be abrogated in lung mesenchyme-specific 
TRII knockout mice in which significant reduction of bleomycin-induced lung fibrosis is 
observed [11, 105]. This suggests a critical role of peroxisomes in experimental lung fibrosis. 
 
1.13. Smad3 deficient mice provide effective protection from BLM- induced 
lung fibrosis  
Excessive TGF-/Smad dependent pathway is well recognized for the fibrotic response in 
IPF, other fibrotic diseases such as dermal fibrosis, as well as in inflammatory processes of 
BLM-induced lung fibrosis [13, 97, 105]. The contribution of Smad3 in development of lung 
fibrosis was identified in vivo, where loss of Smad3 alleviated the bleomycin-induced tissue 
injury and pulmonary fibrosis in mice [13]. Furthermore, lack of Smad3 protected mice from 
BLM induced lung fibrosis, but presented a higher susceptibility for development of 
emphysema by interfering with the physiological role of TGF- in development of alveolar 
structure [108]. These studies suggest that identification of specific downstream profibrotic 
targets of TGF- signaling might be pivotal for using as possible therapeutical targets in 
treatment or attenuation of idiopathic pulmonary fibrosis.  
 
1.14. TR-I constitutively active mice as model to investigate the effect of 
TGF- signal transduction 
TR-I is phosphorylated by TR-II at serines and threonines in the GS domain [109], a 
required step to propagation of signal downstream of TGF-. Different mutations at GS 
domain create constitutively active receptor forms of TR-I [110]. In addition, Bartholin and 
colleagues generated a transgenic mouse with a Cre/loxP inducible constitutively active   
TR-I by using a knock-in strategy into the hypoxanthine phosphoribosyl-transferase locus 
(Hprt) [111]. These transgenic mice are useful tool in addressing the effect of TGF- 
signaling upregulation in any cell type that expresses cre-recombinase [109, 111].  
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1.15. Peroxisomes as ubiquitous organelles in metabolic functions 
Peroxisomes are single membrane bounded ubiquitous organelles, present in all eukaryotic 
cells except spermatozoa and mature red blood cells (Fig.7) [112]. The lung, especially type II 
alveolar epithelial cells and club cells (Clara) possess a large number of peroxisomes [80]. 
Moreover, peroxisomes could also be identified in the apical region of ciliated bronchiolar 
cells as well as in type I alveolar epithelial cells, however, in the latter with less abundance 
and different enzyme composition [80, 112]. In general, these organelles are highly abundant 
in the major metabolic organs, such as hepatocytes in the liver and in epithelial cells of the 
proximal tubules in the kidney [112]. These organelles are highly heterogeneous and their 
enzyme composition and metabolic pathways vary between cell types, tissues and organs 
[112]. In these cell types, peroxisomes are involved in many metabolic functions, including 
degradation of reactive oxygen species (ROS) and bioactive lipid mediators (prostaglandins 
and leukotriens) and synthesis of antioxidant lipids (polyunsaturated fatty acids, 
plasmalogens, etc.) [112]. Peroxisomes might proliferate in number due to metabolic needs or 
impact of different environmental factors [112]. It is well known that, reactive oxygen species 
and nitrogen species induce lung injury due to direct exposure of the lung epithelia to this 
reagents or secondary due to higher oxygen and different environmental oxidants in the 
inspired air, causing oxidation of cellular DNA, proteins and lipids [113]. In this respect, it is 
of interest that deficiency or dysfunction of peroxisomes results in increased cellular oxidative 
stress, accumulation of lipid derivatives normally metabolized in these organelles, leading to 
severe pathological consequences in many organ systems [114, 115].  Different studies have 
shown that in the most severe phenotype of a peroxisome biogenesis disorder (e.g. Zellweger 
syndrome) also mitochondria are compromised in their respiratory function as a secondary 
phenomenon [115]. Moreover, children with Zellweger syndrome (cerebrohepatorenal 
syndrome) develop progressive liver fibrosis or cirrhosis, leading to early death of the patients 
during childhood [115]. Appropriate knockout mouse models exhibit a similar phenotype 
[116]. Most knockout mice with peroxisomal biogenesis defects die during their first day of 
life [116, 117]. Interestingly, in one of the mouse models (PEX11knockout) morphological 
alterations of the lungs were described [117]. Whereas peroxisome deficiency leads to a 
profibrotic phenotype, treatment of rats with a peroxisome proliferator-activated receptor 
alpha (PPAR-) specific agonist evolved a significantly attenuated tubulointerstitial renal 
fibrosis [118]. Many peroxisomal genes contain a PPAR-response element in their promoter 
region by which their transcription can be modified [119].  Independent from the fact that 
peroxisomal metabolism might be affected in other tissue fibrosis, the role of peroxisomes in 
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pulmonary fibrosis onset and progression of this devastating disease has never been described 
[5, 120].  
 
 
Fig.7. Example for a double immunofluorescence staining of peroxisomal biogenesis protein PEX14p 
(green) and alpha-smooth muscle actin (-SMA) (red) in human lung fibroblasts of control subjects 
(picture is taken from results of this thesis). 
 
1.16. Biogenesis of peroxisomes  
The peroxisome biogenesis is a complex biological process, comprising three crucial steps a) 
formation of the peroxisomal membrane, b) import of peroxisomal matrix proteins, c) and 
proliferation of peroxisomes [121]. The peroxisomal proteins are first synthesized on free 
ribosomes and posttranslationally imported into the organelle [122, 123]. The targeting of the 
peroxisomal matrix proteins to the organelle is enabled via cytoplasmic shuttling receptors, 
Pex5p and Pex7p, binding nascent proteins with peroxisomal targeting signals (PTS1 or 
Pex14p DO/-SMA 
18 
 
PTS2) [124]. The biogenesis and the import of matrix proteins into peroxisomes is mediated 
by different biogenesis proteins called peroxins, which are divided into three groups: a) 
peroxins involved in the biogenesis of the peroxisomal membrane, Pex3p, Pex16p and 
Pex19p, [121] b) peroxins that are implicated in the matrix protein import, such as Pex5p, 
Pex7p c) and those that are involved in peroxisome proliferation Pex11p (, , 
 [125] 
(Fig.8). Moreover, Pex11 is known to play an important role in peroxisome proliferation. A 
PPRE is located upstream in the enhancer region of the Pex11 gene [119]. Both, PPAR- 
and PPAR-
 can bind to this element and activate the transcription of Pex11 and perilipin 
genes [119]. Furthermore, Pex13p and Pex14p are biogenesis proteins in the docking complex 
of the peroxisomal membrane, which are critical for the import of peroxisomal matrix 
proteins with targeting signals PTS1 and PTS2 [121, 126]. Mutations in the PEX13 gene in 
humans lead to Zellweger Syndrom. Accordingly, Pex13 knockout mice exhibit a similar 
disease phenotype as the Zellweger Syndrom patients [114, 126].  
 
 
Fig. 8. A schematic illustration of peroxisome biogenesis in mammalian cells. All peroxins are illustrated 
with numbers only [125]. 
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1.17. Peroxisome functions in lipid metabolism and scavenging ROS 
Peroxisomal enzymes are implicated in various metabolic pathways, including scavenging of 
reactive oxygen species (ROS) and reactive nitrogen species (RNS), decomposition of various 
toxic bioactive and pro-inflammatory lipid mediators, as well as in the synthesis of  
cholesterol and ether lipids (plasmologens) [127-129].  The peroxisomes harbor a large 
variety of anti-oxidative enzymes essential in scavenging ROS, such as catalase, glutathione 
reductase, peroxiredoxin I and V, Cu/Zn-SOD [129]. Formerly, SOD2 was also described in 
this organelle, however, recently our group showed that this protein is only present in 
mitochondria and not in peroxisomal matrix [130]. Peroxisomes are intimately involved in 
lipid metabolism by catalyzing 1. Fatty acid alpha-oxidation, 2. Fatty acid beta-oxidation, 3. 
Biosynthesis of polyunsaturated fatty acids, 4. Ether-phospholipid synthesis and 5. Synthesis 
of cholesterol precursors and other isoprenoids [131]. In the peroxisomal β-oxidation 
pathways are oxidized lipid derivatives that are poor substrates for mitochondrial β-oxidation; 
e.g. very long (≥C24; VLCFA) chain fatty acids, branched chain fatty acids, dicarboxylic 
acids, eicosanoids (prostaglandins, leukotrienes), (n-3) and (n-6) polyunsaturated fatty acids 
and bile acid precursors [131]. Peroxisomes also oxidize a large amount of long chain fatty 
acids in situations in which the mitochondrial carnitine-palmitoyl transferase 1 system is 
overloaded or mitochondria are dysfunctional [132, 133]. The fatty acids are usually degraded 
in peroxisomes and thereafter transferred to the mitochondria for complete oxidation [131, 
132]. Peroxisomes are involved in the oxidation of polyamines, D-amino acids, uric acid (in 
non-primates) via several H2O2 producing oxidases and in the detoxification of glyoxylate and 
xenobiotics [132]. An interesting feature of peroxisomes is their ability to adapt their number, 
form and enzyme content in response to nutritional and environmental stimuli, which is 
mediated in part by PPARs [134]. Interestingly, expansion of the peroxisomal compartment 
and upregulation of PEX genes was observed in cells exposed to oxidative stress or ultraviolet 
irradiation [135]. In contrast, significant reduction of catalase is observed in inflammatory 
processes including asthma bronchialis, infections, and allograft rejection and seems to be 
related to the suppressive effect of tumor necrosis factor-α on peroxisome function and 
peroxisome proliferator activated receptor-α [136]. It is well known, that pro and 
antioxidative enzymes are localized in specific subcompartments, such as the plasma 
membrane, the endoplasmic reticulum, peroxisomes or mitochondria and the cytoplasm [129]. 
Interestingly, peroxisomes contain the largest amount  of prooxidative (peroxisomal oxidases 
and iNOS) as well as antioxidative (catalase, SOD 1, Prdx I and Prdx V, glutathione 
reductase) enzymes in their matrix [129, 137]. Moreover, the deficiency of peroxisomes in 
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knockout mice with Zellweger syndrome (PEX 5–/– mouse) leads to mitochondrial defects 
induced by generation of ROS release by the disordered mitochondrial respiratory chain in 
these animals [138]. In addition, lung peroxisomes express a variety of β-oxidation enzymes 
involved in the metabolism of fatty acid derivatives and proinflammatory eicosonaoids [80]. 
Unfortunately, there is scarce knowledge available on the perpetuation and chronification of 
inflammatory reactions in the lung [80]. The role of this cell organelle in the lung and its 
enzyme alterations in IPF patients are not investigated so far, and no comprehensive study has 
been performed on the function of different organelles in IPF. However, alterations in 
peroxisomal metabolism and enzyme content could exert a strong impact on the pathogenetic 
mechanisms in IPF. 
 
1.18. Peroxisomal proteins in human lung 
The alveolar epithelium is of particular interest, because the proliferation of alveolar type II 
cells with concurrent induction of antioxidant enzymes (Mn-SOD, glutathione peroxidase) 
makes the lung tissue resistant to high lethal oxygen concentration, normally lethal to other 
cell types e.g. AECI [136]. This phenomenon is apparently an adaptive response against high 
oxygen concentrations [136]. In the human lung, peroxisomes are highly abundant in alveolar 
epithelial type II cells (AEC II), club (Clara) cells, in both of which they exhibit a high 
catalase expression [80]. Moreover, small peroxisomes are mainly localized in high number in 
the apical region in ciliated cells of the respiratory and bronchiolar epithelium, directly 
underlying the tracheal and bronchial surface, suggesting that they might protect these 
epithelia against the high oxygen content and oxidative damage [112]. Peroxisomes in the 
cells of the alveolar and bronchial regions are also involved in the metabolism of ROS and 
various lipid derivatives and contain high amounts of β-oxidation enzymes as well as ether 
lipid and cholesterol synthesizing enzymes [112]. Peroxisomes might play a critical role in 
regulating the biophysical properties of surfactant through plasmalogen and cholesterol 
synthesis and in the breakdown and homeostasis of bioactive lipids (e.g. proinflammatory 
eicosanoids) and PUFAs with their β-oxidation systems as well as in the maintenance of lipid 
ligand levels for nuclear receptors of the PPAR family [80, 132].  
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1.19. Peroxisomal beta oxidation 
The importance of peroxisomes in lipid metabolism and human health is crucial in 
maintaining the cellular functions by participating in different metabolic pathways such as 
enzymes involved in -oxidation and -oxidation of acyl-CoAs, ether-phospholipid synthesis, 
cholesterol and isoprenoid metabolism and bile-acid synthesis [139, 140]. Moreover, 
oxidation of phytanic acid generates pristanic acid, which undergoes three cycles of 
oxidation in peroxisomes before the chain-shortened fatty acids are exported from the 
peroxisome via the carnitine-dependent route (carnitine O-Octanoyltransferase) or via the free 
acid route through acyl-CoA thioesterases [140, 141] (Fig. 9). Patients suffering from adult 
Refsum´s disease (ARD) are unable to metabolize phytanic acid derived from exogenous 
sources (e.g. cow´s milk), phytanic acid accumulates in tissues and body fluids, due to the 
deficient -oxidation process of phytanic acid to pristanic acid, whereas the subsequent -
oxidation of pristanic acid is normal [140, 142, 143]. Refsum´s disease is characterized by 
atypical retinitis pigmentosa, peripheral polyneuropathy, cerebellar ataxia, and high 
concentration of proteins in the cerebrospinal fluid, therefore phytanic acid accumulation in 
Refsum´s disease can be classified as a true peroxisome disorder [142]. In addition, 
peroxisomes contain a variety of enzymes involved in -oxidation, such as three acyl-CoA 
oxidases (ACOX1, ACOX2, ACOX3), two multifunctional proteins (MFP1, MFP2), and 
several ketoacyl-CoA thiolase (Thiolase A and B, SCPx) [137] (Fig.9). In comparison to the 
peroxisomal -oxidation pathways, mitochondria contain distinct acyl-CoA dehydrogenases 
[144, 145].  
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Fig.  9. The peroxisomal-inducible classical straight-chain and the non inducible branched-chain fatty acid 
β-oxidation systems in humans [145]. D-bifunctional protein (DBP),  l-bifunctional protein (LBP), acyl-CoA 
oxidases 1 (ACOX1), Thiolase A, B (ThioA, ThioB), Peroxisomal Sterol Carrier Protein X (SCPx) 
 
1.20. PPARs in the lung and idiopathic pulmonary fibrosis 
Peroxisome proliferator-activated receptors (PPARs) are a family of ligand-activated 
transcription factors that belong to the nuclear hormone receptor family. They are important 
modulators of the immune system and in cell differentiation and proliferation [146, 147]. 
Three different subtypes of PPARs exist: PPARα, PPARβ/δ and PPARγ. PPARγ has got two 
isoforms, PPAR
1 which is expressed mainly in adipose tissue, while PPAR
2 is more widely 
expressed but is most abundant also in adipocytes [146]. Both are also expressed in different 
cell types in the lung, such as fibroblasts, ciliated airway epithelial cells and AEC II, alveolar 
macrophages, endothelial cells, airway smooth muscle cells, eosinophils, dendritic cells, T-
cells and B-cells [146, 148]. Several other cell types express in addition also PPAR-α and 
PPAR-β/δ such as ciliated bronchial epithelial cells, alveolar macrophages, endothelial cells, 
T-cells and B-cells [146]. PPAR- and PPAR-
 exhibit immunomodulatory properties and 
might play also a role in inflammation and wound healing processes, as well as may function 
as antifibrotic agents [11, 146, 149, 150]. In addition, many recent in vivo studies support the 
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antifibrotic properties of PPAR-γ agonists, who might promote differentiation of lung 
fibroblasts into fat storing lipofibroblasts and inhibit the critical differentiation of fibroblasts 
into myofibroblasts [147]. Furthermore, PPAR-γ ligands, like rosiglitazone and 15d-PGJ2 
induce a lower mortality, reduced histological fibrosis, decreased inflammation with reduced 
α–SMA expression and reduced collagen content in the mouse model of bleomycin-induced 
lung fibrosis [147]. PPAR-γ ligands upregulate the expression of the “phosphatase and tensin 
homologue deleted on chromosome 10“ (PTEN), whose promoter contains a peroxisome 
proliferator response element (PPRE). Moreover, in vitro studies have shown the inhibitory 
effects of PTEN on fibroblast differentiation into myofibroblasts as well as on the reduced 
expression of α-SMA in human and mouse fibroblasts [23, 147]. Thus PPARs might be 
protective therapeutic agents against the progression of IPF. 
 
1.21. Role of PPARs in the prevention of fibrosis  
PPAR- was known to mediate the action of some drugs, mostly hypolipidemic agents that 
proliferate peroxisomes in rodent liver [119]. In addition, PPAR- activates different 
peroxisomal and mitochondrial -oxidation enzymes such as peroxisomal acyl-CoA oxidase 
and peroxisomal 3-ketoacyl-CoA thiolase [151]. In addition, PPAR- is implicated in lipid 
metabolism and was shown to posses important anti-inflammantory properties especially in 
protection and control of airway inflammation [146, 152]. PPAR- resulted also in boosting 
dexamethasone-mediated anti-inflammatory properties [153]. The combination of a PPAR- 
agonist with dexamethasone had significantly increased the anti-inflammatory activity of 
corticoids in mice [153]. In contrast, inflammation was increased in PPAR-knockout mice 
compared to wild-type controls [153]. Furthermore, fenofibrate was shown to reduce the LPS-
induced inflammation in the mouse lung, demonstrated by reduced neutrophil and 
macrophage infiltration [154]. In accordance with the findings above, treatment of PPAR- 
knockout mice with bleomycin resulted in a more severe inflammation and fibrosis 
development than in wild-type mice [155]. These bleomycin-treated PPAR- knockout mice 
exhibited higher levels of cytokines such as TNF-, whereas treatment of mice with PPAR-
agonist WY-14643 significantly reduced inflammation and fibrosis progression [155, 156]. 
Even though several studies have shown beneficial effects of PPARs in the development of 
fibrosis in different organ systems, nobody has studied whether the effect is mediated by 
peroxisomal proliferation and their metabolic activation.    
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1.22. Work hypothesis and aims  
We hypothesized that during idiopathic pulmonary fibrosis, different cytokines, such as 
TNFand TGF- would induce the downregulation of peroxisomal biogenesis- and lipid 
metabolic proteins and that stimulation of the peroxisomal compartment would improve the 
disease progression or alleviate the fibrotic response in patients with IPF.  
 
In detail our specific aims were:  
- To analyze peroxisomal biogenesis proteins (e.g. PEX13p, PEX14p), peroxisomal lipid 
metabolism (e.g. ABCD3, ACOX1), as well as peroxisomal antioxidative enzymes such as 
catalase and others in IPF patients in comparison to control subjects.  
- To study the fibrotic response and TGF- signaling in RNAi-mediated knockdown of 
peroxisomal biogenesis (PEX13) in control and IPF lung fibroblasts.  
- To determine the possible impact of TGF- and other cytokines (TNF-, IL-6) on the 
regulation of peroxisomal biogenesis and metabolism in pulmonary fibrosis.  
- To assess the mechanisms at cellular and molecular level for the regulation of peroxisomal 
gene expression by TGF- signaling.  
- To assess peroxisomal alterations in a bleomycin-induced pulmonary fibrosis mouse model.  
- To analyze the eventual peroxisomal response to bleomycin treatment in TRII KO mice in 
comparison to control littermates.  
- To determine the regulation of peroxisomes by TGF- signaling in TRII and Smad3 
knockout mice, as well as in TGF-receptor I constitutively active mice (TRICA).  
- To study the effects of PPAR--induction and peroxisome proliferation on the fibrotic 
response.  
 
Understanding the mechanisms by which peroxisomes support the cellular protection from 
external toxic agents such as reactive oxygen species or proinflammatory mediators may open 
new treatment strategies for pulmonary fibrosis. By using human IPF and control fibroblast 
cultures as well as the bleomycin-induced mouse lung fibrosis model, this study enhances the 
knowledge on the role of peroxisomes in IPF and provides novel insights into TGF-and 
TNF- induced dysfunction of peroxisomes, as well as in understanding the molecular 
pathogenesis of IPF.  
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2. Material and methods 
2.1. Materials 
2.1.1. General instruments, materials and reagents  
All chemicals used in the thesis were of analytical grade purity. Detailed chemicals, reagents 
and consumables are specified along the methodology below.  
All instruments, general materials as well as chemicals and enzymes are listed in table I.  
General materials  Company name  
Cell culture 6 well plate  Becton Dickinson GmbH, Heidelberg, Germany  
Cell culture 12 well plate  Becton Dickinson GmbH, Heidelberg, Germany  
Cover slips  R. Langenbrinck, Emmendingen, Germany  
Gibco´s Dulbecco´s Modified Eagle 
Medium, (DMEM), High glucose  
Sigma, Steinheim, Germany  
Dimethyl sulfoxide (DMSO)  Invitrogen Life Technologies GmbH, Karlsruhe, 
Germany  
Eppendorf tubes  Eppendorf AG, Hamburg, Germany  
Falcon tubes  Becton Dickinson, Heidelberg, Germany  
Filter tips  Braun, Melsungen, Germany  
Microscope slides  R. Langenbrinck, Emmendingen, Germany  
Nitrile gloves  Kimberly-Clark Professional, Koblenz-
Rheinhafen, Germany  
Pasteur pipettes  VWR International GmbH, Darmstadt, Germany  
Petri dishes  Becton Dickinson GmbH, Heidelberg, Germany  
Plastic pipettes, for cell culture (sterile)  Becton Dickinson GmbH, Heidelberg, Germany  
Phosphate-buffer saline (PBS)  PAA laboratories GmbH, Pasching, Austria  
Syringe filters 0.22 microns  Millipore GmbH, Schwalbach, Germany  
Chemicals and enzymes  Company name  
Agarose  Roche, Grenzach-Wyhlen, Germany  
Bovine serum albumin (BSA)  Carl-Roth GmbH & Co, Karlsruhe, Germany  
Disodium hydrogen phosphate 
(Na2HPO4)  
Merck, Darmstadt, Germany  
Ethanol  Riedel-de-Haën, Seelze, Germany  
Ethidium bromide  Fluka, Neu-Ulm, Germany  
Ethylene diamine tetraacetic acid 
(EDTA)  
Fluka, Neu-Ulm, Germany  
Fetal calf serum (FCS)  PAA laboratories GmbH, Pasching, Austria  
Gibco´s 0.25% Trypsin/EDTA  Invitrogen Life Technologies GmbH, Karlsruhe, 
Germany  
Glycine  USB Europe GmbH, Staufen, Germany  
LǦGlutamate  Cambrex BioScience, MD, USA  
N-propyl-gallate  Sigma, Steinheim, Germany  
Mowiol 4-88  Polysciences Europe GmbH, Eppelheim, Germany  
Paraformaldehyde (PFA)  Sigma, Steinheim, Germany  
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Pencillin/ streptomycin  PAA laboratories GmbH, Pasching, Austria  
Potassium dihydrogen phosphate 
(KH2PO4)  
Carl-Roth GmbH & Co, Karlsruhe, Germany  
Sodium chloride (NaCl)  Carl-Roth GmbH & Co, Karlsruhe, Germany  
Taq DNA polymerase  Invitrogen, Heidelberg  
Triton X-100  Sigma, Steinheim, Germany  
Trypan blue  Sigma, Steinheim, Germany  
Trypsin  Sigma, Steinheim, Germany  
Tween 20  Fluka, Steinheim, Germany  
1 kb Ladder  Promega, Germany  
Potassium chloride (KCl)  Sigma, Steinheim, Germany  
Tris (trishydroxymethylaminomethane)  Sigma, Steinheim, Germany  
Instruments used  Company name  
Bio-Rad electrophoresis apparatus  Bio-Rad, Heidelberg, Germany  
Dish washing machine  Miele, Gütersloh, Germany  
Cary 50 Bio-UV-visible 
spectrophotometer  
Varian, Darmstadt, Germany  
Gel-Doc 2000 gel documentation system  Bio-Rad, Heidelberg, Germany  
Hera cell 240 incubator  Thermo Scientific Corporation, MA, USA  
Hera safe, clean bench  Thermo Scientific Corporation, MA, USA  
Ice machine  Manitowoc Ice UY-0140A, USA  
iCycler PCR machine  Bio-Rad, Heidelberg, Germany  
Leica DMRD fluorescence microscope  Leica Microsystems GmbH, Wetzlar, Germany  
Leica TCS SP5 confocal laser scanning 
microscope  
Leica Microsystems GmbH, Wetzlar, Germany  
Magnetic stirrer, MR3001  Heidolph Instruments GmbH & Co.KG, 
Schwalbach,Germany  
Microwave oven  LG Electronics GmbH, Austria  
Mini centrifuge  Carl-Roth GmbH & Co, Karlsruhe, Germany  
pH Meter  IKA® Werke GmbH & Co. KG, Staufen, Germany  
Pipettes  Eppendorf AG, Hamburg, Germany  
Pipette tips  Eppendorf AG, Hamburg, Germany  
Power supply -200, 300 and 3000 Xi 
Bio-Rad, Heidelberg, Germany  
Bio-Rad, Heidelberg, Germany  
Pressure/ Vacuum Autoclave FVA/3  Fedegari, Albuzzano, Italy  
SmartspecTM 3000 spectrophotometer  Bio-Rad Laboratories GmbH, München, Germany  
T25 basic homogenizer  IKA, Staufen, Germany  
Vortex M10  VWR International GmbH, Darmstadt, Germany  
Water bath GFL 1083  GFL Gesellschaft für Labortechnik mbH, 
Burgwedel, Germany  
Table I. General materials, chemicals, enzymes and instruments used in experiments  
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2.1.2.  Buffers and solutions 
All buffers and solutions used in this thesis are listed in table II.  
Name of solution  Composition  
Solutions for cell culture & morphology  
Perfusion fixative solution (PFA)  4% PFA in 1X PBS (150 mM NaCl, 13.1 mM 
K2HPO4, 5 mM KH2PO4), pH 7.4  
10 X PBS  1.5 M NaCl, 131 mM K2HPO4, 50 mM 
KH2PO4, pH 7.4  
Trypsin (0.01%)  Fresh 0.01 g trypsin in 100 ml of 1X PBS 
buffer  
Blocking buffer-4% PBSA +  
0.05% Tween 20  
8 g BSA in 200 ml of 1X PBS and  
Tween 20  
Dilution buffer- 1% PBSA +  
0.05% Tween 20  
2 g BSA in 200 ml of 1X PBS and 
Tween 20  
Mowiol 4Ǧ88 solution  16.7 % Mowiol 4Ǧ88 (w/v) in 80 ml of 1X 
PBS, 40 ml of glycerol will be added, and 
centrifuged at 15,000U/min for 1 h, the 
supernatant was stored at Ǧ20°C prior use.  
AntiǦfading agent 2.5 % NǦpropylǦgallate in 1X PBS and add 50 
% of glycerol  
Mounting medium for immunofluorescence 3 parts of Mowiol 4Ǧ88 + 1 part of antiǦfading 
agent  
Solutions for biochemistry  
Homogenization buffer (HMB)  To 50 ml of 0.25 M sucrose and 5 mM MOPS 
(pH 7.4) add only before use 500 μl 100 mM 
EDTA + 50 μl 100% ethanol + 5 μl 2 M DTT 
+ 50 μl 1 M aminocaproic acid and 100 μl 
cocktail of protease inhibitors  
Cell lysis buffer (1X) 
 
50mM Tris +150mM Nacl +1% Triton-X-100 
(pH 7.4). Before use 10% protease inhibitor 
cocktail was added. 
Resolving gel buffer A  1.5 M Tris-HCl, pH 8.8 + 0.4% SDS  
Stacking gel buffer B  0.5 M Tris-HCl, pH 6.8 + 0.4% SDS  
12 % resolving gel (for 4 SDS-PAGE gels)  8 ml of 30% acrylamide + 10 ml of buffer A 
+ 2 ml of ddH2O + 15 μl of TEMED + 130 μl 
of 10% APS  
Stacking gel (for 4 SDS-PAGE gels)  1.25 ml of 30% acrylamide + 5 ml of buffer B 
+ 5 ml of distilled H2O + 15 μl of TEMED + 
130 μl of 10% APS  
10X Sample buffer  3.55 ml ddH2O + 1.25 ml 0.5 M Tris-HCl, pH 
6.8 + 2.5 ml 50% (w/v) glycerol + 2.0 ml 
10% (w/v) SDS + a pinch of 0.05% 
bromophenol blue. Before use add 50 ml 
β-mercaptoethanol  
10% Blocking buffer  10 g fat free milk powder in 100 ml of ddH2O  
10X Electrophoresis buffer  250 mM Tris + 2 M glycin + 1% SDS  
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20X Transfer buffer  Bis-Tris-HCl buffered (pH 6.4) 
polyacrylamide gel; NuPAGE transfer buffer, 
Invitrogen, Heidelberg, Germany  
10X TBS  0.1 M Tris in 0.15 M NaCl in, pH 8.0  
1X Washing buffer (TBST)  10 mM Tris/HCl, 0.15 M NaCl, 0.05% Tween 
20, pH 8.0  
Stripping buffer 62.5 mM Tris, 0.2 % SDS, 42°C in a water 
bath for 40 min pH 6.8  
Table II. Chemical reagents and buffers employed in experimental setup 
 
2.1.3. Recombinant cytokines and drugs 
Recombinant cytokines and drugs used in this thesis are summarized in table III.  
 
Cytokines, drugs Application Concentration Vehicle Company 
Ciprofibrate PPAR- agonist 200 mM DMSO Sigma-Aldrich, 
Missouri-USA 
GW6471 PPAR- 
antagonist 
10 mM DMSO Tocris, United 
Kingdom  
Luteolin Inhibitor of Nrf2  100 mM Ethanol Sigma-Aldrich, 
Missouri-USA 
LY364947 Inhibition of  
TGF-1 signaling 
5 mM DMSO Tocris, United 
Kingdom 
rHuIL-6 Activation of 
Interleukin 6 
200 μg  4 ml pyrogen 
free ddH2O 
Biomol, Germany  
rhTGF-1 Activation of 
TGF-1 signaling  
20 μg/ml  4 mM HCl +  
1 mg/ml BSA 
R&D, USA 
rHuTNF- Activation of 
TNF- signaling 
100 μg/ml 18 MΩ-cm H2O Biomol, Germany 
SR11302 Inhibitor of 
activator protein-1 
(AP-1) 
10 mM DMSO Tocris, United 
Kingdom 
WY14643 PPAR- agonist 100 mM DMSO Tocris, United 
Kingdom 
Table III. Recombinant cytokines and drugs 
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2.1.4. siRNA 
The following siRNAs were used to knockdown peroxisomal biogenesis and as controls in 
table IV.  
siRNA pmol/transfection Provider 
PEX13 siRNA 150 Ambion AM16708, Darmstadt, 
Germany 
PEX13 siRNA 150 Ambion AM16773, Darmstadt, 
Germany 
silencer select negative 
RNA 
150 Ambion, Cat#4390843,  Darmstadt, 
Germany 
Table IV. siRNAs applied for cell transfection 
 
2.1.5. Luciferase reporter and expression plasmids  
The following luciferase reporter and expression plasmids are shown in table V.  
Plasmid Description Institute /Company name 
COL1A2-luc Collagen 1A2 Dr. Eunsum Jung (BioSpectrum LifeScience 
Institute, Korea) 
pARE-luc Antioxidant response 
element reporter plasmid 
Dr. William E. Fahl (University of 
Wisconsin, Madison, WI, USA) 
pAP-1-luc Activator protein 1 reporter 
plasmid 
Dr. Craig A. Hauser (The Burnham Institute, 
La Jolla, CA) 
pGL2 basic Empty vector negative 
Control 
Promega, Madison, WI, USA 
pGL3 basic Empty vector negative 
Control 
Promega, Madison, WI, USA 
pGL4 basic Empty vector negative 
Control 
Promega, Madison, WI, USA 
PPAR reporter 
luciferase Kit 
PPAR reporter  Qiagen Cignal PPAR Reporter,  
Kit: CCS-3026L 
pRL-SV40 
Vector 
pRL Renilla luciferase 
control reporter vector 
Promega, Madison, WI, USA 
SBE-luc Smad binding element 
reporter plasmid  
Dr. Bert Vogelstein (Johns Hopkins Kimmel 
Cancer Center Baltimore, MD, USA) 
pSG5 PPAR 
alpha 
PPAR- expression plasmid Addgene plasmid # 22751 
Table V. Luciferase reporter and expression plasmids  
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2.1.6. Transfection reagents 
The following transfection reagents were used for siRNA and plasmid transfection in table 
VI.  
Reagent Application Company 
Interferin siRNA transfection Reagent Peqlab, Erlangen, Germany 
TransIT-LT1 plasmid transfection reagent Mirus Bio LLC, WI, USA 
Attractene plasmid transfection reagent Qiagen, Hilden, Germany 
Table VI. Transfection reagents  
 
2.1.7. Kits  
The list of kits used in this thesis with corresponding suppliers in table VII.  
Kits Company name 
Dual luciferase kit Promega, Madison, WI, USA 
Human IL-6 Quantikine ELISA Kit R&D, Systems Inc. Minneapolis, USA 
Human TGF-1 immunoassay R&D, Systems Inc. Minneapolis, USA 
qPCR kit Qiagen, Hilden, Germany 
QIAGEN Plasmid midi kits Qiagen, Hilden, Germany 
Rneasy kit Qiagen, Hilden, Germany 
RT-PCR kit Invitrogen, Karlsruhe, Germany 
Sircol Soluble Collagen Assay  Biocolor, Northern Ireland, UK 
Table VII. Molecular and cellular biology kits  
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2.1.8. Antibodies 
The list of antibodies used for immunofluorescence, Immunohistochemistry and Western 
blots are summarized in table VIII.  
Antigens  Species AB raised in Dilution Supplier 
-SMA Mouse, monoclonal  (IF) 1:2,000 
(WB) 1:2,000 
Sigma, Missouri, USA Cat. A2547 
ABC-transporter D3 
(abcd3), mouse  
Rabbit, polyclonal (IF) 1:100  Gift from Alfred Völkl, University of 
Heidelberg, Germany 
Acyl-CoA oxidase 1 
(ACOX1), mouse 
Rabbit, polyclonal (IF) 1:1000  Gift from Paul P. van Veldhoven, Dept. of 
Molecular Cell Biology, Pharmacology, 
Catholic 
Catalase (CAT), mouse  
 
Rabbit, polyclonal (IF) 1:2,000  
(WB)1:10,000 
Gift from Denis I. Crane, School of 
Biomol. Biophys. Sci., Griffith Univ., 
Nathan, Brisbane, Australia 
Catalase (CAT), human Rabbit, polyclonal  (IF) 1:250 Polyscience (Cat:23728) 
Collagen I, mouse Rabbit, polyclonal (IF) 1:500  
(WB) 1:500  
Novus Biologicals, Cat. No: NB600-408 
Collagen III, mouse Rabbit, polyclonal (IF) 1:500  Novus Biologicals, Cat. No: 
Glutathione  reductase  
(GR), mouse 
Rabbit, polyclonal (IF) 1:500  Abcam/Biozol (Cat:ab16801) 
Glyceraldehyde 3-
phosphate 
dehydrogenase 
(GAPDH), rabbit  
Mouse, monoclonal  (WB) 
1:10,000  
HyTest Ltd, Turku, Finland, Cat. No: 5G4 
Heme oxygenase 1 
(HO-1), rat  
Rabbit, polyclonal  (IF) 1:1,000  Assay Designs, Inc. Michigan, 
USA,Cat.no:SPA-895 
Ki67, mouse  
 
Rat, monoclonal  (IF) 1:600 Dakocytomation, Denmark, Cat, no: 
M7249 
c-Myc, human Mouse, monoclonal (IHC) 1:250 Santa Cruz Biotechnology, Oregon, USA 
(9E10): sc-40 
Nuclear factor erythroid 
2-related factor 2 
(Nrf2), human  
Rabbit, polyclonal (IF) 1:250  Santa Cruz Biotechnology Inc. Heidelberg, 
Germany, Cat. No:sc-13032 
Peroxisomal biogenesis 
factor 13 (Pex13p), 
mouse  
Rabbit, polyclonal  (IF) 1:2,000  
(WB) 1:6,000 
Gift from Denis I. Crane 
Peroxisomal biogenesis 
factor 14 (Pex14p), 
mouse  
Rabbit, polyclonal  (IF) 1:4,000 
(IHC) 1:4000 
(WB)1:10,000  
Gift from Denis I. Crane 
Prolyl 4-hydroxylase 
(PDI), mouse 
Rabbit, polyclonal  (IF) 1:100  Acris (AP08767PU-N) 
Smad3, mouse Rabbit, polyclonal  (IF) 1:50  Cell signalling (Cat:9523) 
Superoxide dismutase 2 
(SOD2), rat  
 
Rabbit, polyclonal  (IF) 1:5,000 Research Diagnostics, Inc., NJ, USA, Cat. 
No: RDI-RTSODMabR 
Table VIII. Antibodies for Western blotting (WB), Immunohistochemistry (IHC) and 
immunofluorescence (IF) 
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2.1.9. Secondary antibodies and counterstaining of nuclei 
The list of secondary antibodies and counterstaining of nuclei used in this thesis are presented 
below in table IX.  
Secondary detection system Host Method Dilution   Supplier 
Anti Rabbit-IgG Alexa Fluor 
488 
Donkey IF 1:600 Molecular Probes/Invitrogen, Cat. No: 
A21206 
Anti-Mouse-IgG 
AlexaFluor555  
Donkey  IF  1:1,000  Molecular Probes/Invitrogen, Cat. No: 
A31570 
Rabbit biotinylated IgG  Goat IHC 1:250 Rabbit Extravidin kit, Sigma, Steinheim, 
Germany, Cat. No: B6648 
Extravidin  Rabbit IHC 1:250 Rabbit Extravidin kit, Sigma, Steinheim, 
Germany, Cat. No: E8386 
Anti mouse IgG alkaline 
phosphatase  
Goat WB 1:20,000 Sigma, Steinheim, Germany. Cat. No: 
A3562 
Anti rabbit IgG alkaline 
 phosphatase  
Goat WB 1:20,000 Sigma, Steinheim, Germany. Cat. No: 
A3562 
Counterstaining of nuclei for 
IF 
    
Hoechst 33342 (1 μg/ml) 
nucleic acid staining 
- - - Molecular Probes/Invitrogen, Cat. No: 
33342 
TOTO-3 nucleic acid staining, 
1:1,000 
- - - Molecular Probes/Invitrogen, Cat. No: 
T-3604 
Table IX. Secondary antibodies and nuclear stains  
 
2.1.10. Primers 
Human and mouse primers used for RT-PCR and qRT-PCR are summarized in table X-XII.  
Gene  Primer Annealing (°C) Length (bp) 
PEX13 For: TCAGCAAGCTGAAGAAAGCA 
Rev: CTGCAGGCAAACATGAAAGA 
61,5 434  
TGF-1 For:GGATAACACACTGCAAGTGGAC 
Rev: GGGTTATGCTGGTTGTACAGG 
58,7 330 
COL1A2 For:TCAGAACATCACCTACCACTGC 
Rev:GTCCAGAGGTGCAATGTCAAG 
61,5 300 
IL-6 For: AGGAGACTTGCCTGGTGAAA 
Rev: CAGGTTTCTGACCAGAAGAAGG 
61,5 370 
MMP2 For: TACTGGATCTACTCAGCCAGCA 
Rev: CTTCAGGTAATAGGCACCCTTG 
61,5 300 
28S rRNA For: AAACTCTGGTGGAGGTCCGT 
Rev: CTTACCAAAAGTGGCCCACTA 
63 250 
HPRT For: AAGCTTGCTGGTGAAAAGGA 
Rev: AAGCAGATGGCCACAGAACT 
61,5 260 
Table X. Human primers for RT-PCR 
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Gene  Primer Annealing (°C) Length (bp) 
PEX13 For: CCATGTAGTTGCCAGAGCAG 
Rev: CATCAAGGCTAGCCAGAAGC 
61,5 140 
PEX14 For: CTGCCTTTGGCTTTGATCTC 
Rev: CGTGGTGTCACGGTAGTCAA 
61,5 137 
TGF-1 For: GGATAACACACTGCAAGTGGAC  
Rev: GGGTTATGCTGGTTGTACAGG 
61,5 330 
COL1A2 GGTATAGGAGCTCCAAGGACAA 
GCAGCCATCTACAAGAACAGTG 
61,5 305 
TNF- For: TCTACTCCCAGGTCCTCTTCAA  
Rev: AGACTCGGCAAAGTCGAGATAG 
61,5 269 
IL-6 For: AGGAGACTTGCCTGGTGAAA  
Rev: CAGGTTTCTGACCAGAAGAAGG  
61,5 370 
28S 
rRNA 
For: AAACTCTGGTGGAGGTCCGT  
Rev: CTTACCAAAAGTGGCCCACTA 
63 250 
Table XI. Human primers for qRT-PCR 
 
Gene  Primer Annealing (°C) Length (bp) 
mPEX14 For: CACTGGCCTCTGTCCAAGAGCTA 
Rev: CTGACAGGGGAGATGTCACTGCT 
 
61,5 298 
mCatalase For: GCAGATACCTGTGAACTGTC 
Rev: GTAGAATGTCCGCACCTGAG 
 
58,7 103 
Table XII. Mouse primers for qRT-PCR 
 
2.2. Methods 
2.2.1. Cell culture and tissue sections  
In this thesis work, human lung tissue (cryosamples and paraffin embedded tissue) and 
fibroblasts from patients with IPF or control organ donors were used, obtained from the 
Giessen DZL-biobank (Deutsches Zentrum für Lungenforschung) at UGMLC (University of 
Giessen and Marburg Lung Center). Directly after lung transplantation tissue samples were 
snap frozen in liquid nitrogen or placed in 4% (w/v) paraformaldehyde in PBS buffer, pH 7,4. 
Control and IPF fibroblasts were cultured in Dulbecco’s Modified Eagle’s Medium (DMEM) 
with  low glucose supplemented with 2 mM L-glutamine, 10 U of penicillin/ml, 100 μg of 
streptomycin/ml, 10% FBS and maintained at 37°C with 5% CO2 for different time-points as 
described below.  
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Medium composition  
The compositions of the medium and corresponding suppliers are listed in table XIII.  
Product Uses Company  
10 % Fetal Bovine Serum Growth promoting and 
survival  
PAA laboratories, United 
Kingom 
1% Penicillin Streptomycin  Antibacterial agent Gibco, USA 
  L-Glutamine  additive component       Merck-Millipore, Germany 
Table XIII. Cell culture medium supplements 
 
2.2.2. Isolation of control/IPF fibroblasts  
Primary human control (n=10) and IPF fibroblasts (n=10) were isolated from human lung 
tissue biopsies obtained from patients undergoing lobectomy or pneumectomy. Tissues were 
cut in small slices, placed in cell culture flasks and cells regularly grown out from the tissue 
slices after 1 week and passaged thereafter by standard trypsinization. Isolated human lung 
fibroblasts were frozen in passage 3 or 4 until use. Fibroblasts were plated onto 10-cm2 cell 
culture dishes and grown until confluency. They were passaged or plated for the respective 
experiments described below. For all experiments, fibroblasts cells were used before until the 
eighth passage.  After passaging, cells were grown for 24 hours before undergoing any 
treatment with above mentioned reagents or siRNA transfection.  
 
2.2.3. Freezing of cells  
Human control and IPF lung fibroblasts were cultivated at 5% CO2 until confluency and 37°C 
and passaged by trypsinization with Gibco´s 0.25% Trypsin/EDTA for 3 minutes at 37°C. 
After trypsinization, the cells were detached using 6 ml of fresh medium and centrifuged at 
200 g for 5 min. Meanwhile the freezing solution was prepared in a ratio of 70% fresh 
DMEM medium, 20% of FBS and 10% of dimethyl sulfoxide (DMSO). The freezing solution 
was kept at 4°C for 20 minutes prior to use. The cell pellets were resuspended in the freezing 
solution and frozen in Nalgene cryobox filled with isopropanol at -80°C overnight. The next 
day, the cryotubes were transferred to liquid nitrogen for long-term storage. 
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2.2.4. Poly –L-lysine coating  
Coverslips were placed in 12 well or 24 well Petri dishes. 10 mg of poly-L-lysine 
hydrobromide was dissolved in 100 ml of 0.1 M borate buffer and filtered with Millipore 
syringe filters of 0.22 μm. Thereafter 2 ml of the solution was added to the sterile coverslips. 
The incubation of Petri dishes with cover slips was done overnight under a laminar flow. 
After 24 h the dishes were washed twice with dd H2O, left in ddH2O for 5 h and thereafter 
washed again 2 x 5 min with dd H2O, followed by aspiration of water drops and air drying 
prior to storage.  
 
2.2.5. Mice  
(The experimental work in transgenic mice and bleomycin induced pulmonary fibrosis was 
performed during my laboratory rotation at Saban Research Institute of Children’s Hospital 
Los Angeles, California, USA).  
 
C57BL/6J wild type mice, 8 wk of age, were kept under specific pathogen-free conditions at 
the animal facility of Children’s Hospital Los Angeles. Floxed-TGF-β receptor II (TRII) 
mice were provided by Dr. Harold Moses at Vanderbilt University [157], in which Exon 2 and 
Exon 3 of the TRII gene were floxed [157, 158]. The mice were crossed with Tbx4-
rtTA/TetO-Cre driver line [107], and lung mesenchyme-specific deletion of TRII Exon 2/3 
was achieved upon doxycycline administration [105]. Smad3 null mutant (-/-) mice were bred 
from C57BL/6 heterozygous mice with deletion of exon 1 in the Smad3 gene [13]. Transgenic 
mouse strain containing constitutively active TGF- I receptor (TRICA) were provided by Dr. 
Laurent Bartholin at University of Lyon [111]. LoxP-STOP-loxP-TRICA mice were 
generated by using a knock-in strategy into the X chromosome-linked hypoxanthine 
phosphoribosyl-transferase locus (Hprt). By crossing with Tbx4-rtTA/TetO-Cre driver line, 
the STOP cassette was excised specifically in lung resident mesenchymal cells upon 
doxycycline-induced Cre expression, which resulted in TRICA transgene expression under 
control of CAG (human cytomegalovirus enhancer and chicken -actin) promoter [111]. Mice 
were monitored regularly and received food and water ad libitum (n=3 for each strain). Mice 
were anesthetized with isoflurane inhalation, were administered with 4 U/kg bleomycin 
(Sigma, St. Louis, MO) diluted in 120 μl of saline, or saline alone by intratracheal instillation 
using an intratracheal aerosolizer (MicroSprayer® Aerosolizer – Model IA, Penn-Century, 
Wyndmoor, PA on day 0 [105]. Lungs were removed for protein and mRNA isolation or 
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immersion fixed overnight in 4% paraformaldehyde fixative in PBS (pH 7.4) and embedded 
in paraffin (Paraplast Plus, St. Louis, MO) for histological analysis. Animal protocols used in 
the experiments were approved by the Institutional Animal Care and Use Committee at 
Children’s Hospital Los Angeles.  
 
2.2.6. Bleomycin-induced pulmonary fibrosis  
Three female C57BL/6J control and TGF- receptor II (TRII) knockout mice (8-week-old), 
anesthetized with isoflurane inhalation, were administered with 4 U/kg bleomycin (Sigma, St. 
Louis, MO) diluted in 120 μl of saline, or saline alone by intratracheal instillation using an 
intratracheal aerosolizer (MicroSprayer® Aerosolizer – Model IA, Penn-Century, Wyndmoor, 
PA) on day 0 [105]. The mouse lungs were then harvested 7, 14 and 28 days post bleomycin 
treatment. The bleomycin dose used in the experiment was shown to produce pulmonary 
fibrosis consistently with a low mortality rate of the animals (10%) [13]. Lungs were 
immersion-fixed in 4% PFA in PBS (pH 7.4) at 4°C overnight, then dehydrated and 
embedded in paraffin. Paraffin sections of 5 m thickness were cut on a sliding microtome 
and used for immunofluorescence staining [105]. 
 
2.2.7. Isolation of mouse fibroblasts 
C57BL/6J mouse primary lung fibroblasts from TRII, Smad3 wild-type and knockout as well 
as from TRI wild-type and TRICA were isolated from lung tissues of pathogen-free 
laboratory mice. Lungs were perfused with PBS from right ventricle, and transferred the 
deblooded lung to a sterile dish. The minced tissue to 1 mm3 was washed with ice-cold PBS 
and centrifuged at 1600 rpm for 6 min. The supernatant was discarded. Then, the minced 
tissue was digested with digestion solution at 37 °C for 60 min (shaking in water bath, by 
pipetting every 10 min). The digestion solution was prepared in Ca/Mg-free PBS, containing 
Dispase II 2 mg/ml (Roche), Collagenase I 1 mg/ml (Sigma), Dnase Type I 0,16 mg/mg 
(Sigma). The digested tissue was filtered with 70 μm cell strainer, and washed with 10 ml of 
DMEM/F12 medium containing 10 % FBS. Cells were centrifuged at 1600 rpm for 6 min, 
then washed in DMEM/F12 medium containing 10 % FBS, and  centrifuged again at 1600 
rpm for 6 min. Cells were resuspended in DMEM/F12 medium containing 10 % FBS, plated 
at the density 105/cm2 in plastic culture flask T75 for 1 h at 37 °C. The unattached cells were 
removed by aspirating off the medium, the plate was washed again with fresh medium and 
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aspirated off again. Finally DMEM/F12 containing 10 % FBS was added and cell were 
incubated in culture at 37 °C, 5% CO2 for 3-5 days. Primary lung fibroblasts were used in 
assays of standard biochemical procedures performed with cell cultures including qRT-PCR, 
Western blotting and immunofluorescence staining. Epithelial and endothelial cell 
contamination was checked be cytokeratin staining.  
 
2.2.8. PEX13 siRNA transfection of control and IPF fibroblasts for Western blot- 
and qRT-PCR-analyses and cytokine measurements   
Human control and IPF lung fibroblasts were cultured in 12-well or 24-well plates (BD 
Falcon #353043), at 8x104 cells/well or 4x104 for 24 hours in normal media (DMEM 1x, 
Gibco) low glucose medium supplemented with 2 mM L-glutamine, 10 U of penicillin/ml, 
100 μg of streptomycin/ml, 10% FBS) and maintained until 70-80 % confluency at 37 °C with 
5% CO2. Briefly, siRNA pools for PEX13 knockdown (same amount of PEX13 siRNA 1 and 
2) were incubated with the Interferin siRNA Transfection Reagent (Peqlab, Cat; 13-409-10) in 
basal media with no serum or antibiotics and allowed to form complexes for 15 min at room 
temperature. The complexes were then added to the cell suspension for each well (final 
siRNA concentration of 15 nM). After 24 h, cells were transfected for the second time with 
the same pool of PEX13 siRNA. After 72 h from the first transfection, cells were collected by 
centrifugation (200 g for 5 min at RT) and the pellet processed further for RNA- or protein 
isolation. The supernatants were used for cytokine and collagen assays. For 
immunofluorescence and DHE staining, cells were grown on poly-L-lysine coated coverslips. 
After siRNA treatment they were fixed with the above mentioned 4% PFA-fixative and 
processed as described in IF.       
 
2.2.9. rhTGF-1 treatment  
The human control and IPF pulmonary fibroblasts were cultured in the same manner as 
described above for the rhTGF- treatment studies. After 24 h, cells were challenged with 5 
ng/ml rhTGF-1 for an additional 24 h. 1 h prior to TGF- treatment cells were treated with 
specific inhibitors: 5μM LY364947 (Tocris Cat: 2718) TGF- inhibitor, 10 μM SR11302 
(Tocris, Cat.No.2476) an inhibitor of activator protein-1 (AP-1) transcription factor activity, 
or 25 μM Luteolin (Sigma, L9283), an Nrf2 inhibitor. Cells were further processed for 
immunofluorescence, RNA and protein isolation and supernatants were collected for cytokine 
ELISA according to manufacturers´ instructions. For TGF-1-induced ROS production 
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studies, cells were treated for 30-60 minutes with TGF-1, after which they were undergoing 
staining with (DHE) in a final concentration of 5 μM (see below). 
 
2.2.10. TNF- treatment  
Cells were seeded as described previously at a density of 8 x 104 cells/well in 12-well plates. 
After 24 h, they were challenged with 10 ng/ml human rHuTNF- (Biomol Cat: 50435) for 
different time points: 0 h, 1 h, 4 h and 6 h duration [99]. At the end of the incubation period, 
the cells were processed for RNA isolation, protein analysis with Western blotting and 
luciferase reporter assays.  
 
2.2.11. IL-6 treatment  
IPF fibroblasts were seeded as described previously at a density of 8 x 104 cells/well in 12-
well plates. After 24 h, they were challenged with 20 ng/ml recombinant human IL-6 
(Biomol, Cat: 50435) for 6 h duration. At the end of incubation period, the cells were 
processed for protein analysis with Western blotting.  
  
2.2.12. PPAR- agonist (ciprofibrate, WY14643) and PPAR- antagonist 
(GW6471) treatment 
The experiments were performed on control and IPF fibroblasts from the 2nd-8th passages. 
Cells were seeded for 24 h in 12-well and 24-well plates as described above. Cells were then 
treated with ciprofibrate (Sigma-Aldrich Chemie GmbH) for 48 h with the indicated 
concentrations: 0 μM, 150 μM, 300 μM, 600 μM, WY14643 (Tocris, Cat.No.1312) for 48 
hours with the indicated concentrations: 0 μM, 50 μM, 100 μM, 200 μM, or with GW6471 
(Tocris Cat: 4618) for 24 h with the indicated concentrations: 0 μM, 5 μM, 10 μM. After 
respective treatments, cells were processed for immunofluorescence and protein isolation. For 
the experiments of TGF- treatment with combined PPAR-agonists or antagonist 
pretreatment, IPF cells were either pretreated with ciprofibrate (200 μM) or WY14643 (100 
μM) for 48 h after which the medium was replaced with serum free medium alone or serum 
free medium containing the PPAR- antagonist GW6471 (10 μM) for an additional 1 h. 
Fibroblasts were treated for 2 h with ciprofibrate (200 μM), WY14643 (100 μM) in serum 
free medium, which was followed by the addition of TGF-β1 (5ng/ml) for 24 h.  
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2.2.13. Immunohistochemistry  
Mouse lungs from TRI WT and TRICA were fixed by perfusion via the right ventricle of the 
heart with 4% paraformaldehyde in PBS (pH 7.4) and embedded into paraffin. Tissue sections 
of 5 μM thick were used for immunohistochemistry staining. Paraffin tissue sections were 
deparaffinized followed by blocking of the endogenous peroxidase (3% H2O2 for 10 min). 
Sections to be stained for PEX14 and c-Myc were treated with blocking goat serum for 1 h 
and incubated overnight with primary antibody dissolved in PBS/BSA at 4°C. The rabbit 
polyclonal antibody against PEX14 and the mouse monoclonal antibody against c-Myc were 
used accordingly (see table VIII). The next day, sections were washed with PBS to remove 
unbound primary antibody, followed by incubation of sections for 1 h with biotinylated anti-
mouse or anti-rabbit secondary antibody. After careful washing with PBS, the sections were 
incubated with Extravidin peroxidase at RT. The peroxidase activity was visualized by using 
diaminobenzidine for peroxidase. Nuclei were counterstained with hematoxylin. Normal 
rabbit IgG, bovine serum albumin, and water were used in parallel slides as negative controls.  
 
2.2.14. Immunofluorescence  
Control and IPF fibroblasts were plated on poly-L-lysine (Sigma Aldrich GmbH, Steinheim 
Germany) coated coverslips in 24 well plates for 24 h and thereafter treated with rhTGF-1 
(R&D Cat: 240-B), LY364947 (Tocris Cat:2718), rHuTNF-a (Biomol Cat: 50435), 
ciprofibrate (Sigma), WY14643 (Tocris, Cat.No.1312), GW6471 (Tocris Cat:4618) for the 
indicated time points as described above. Thereafter, they were subjected to an indirect 
immunofluorescence staining protocol as previously described [80, 159]. Briefly, cells were 
washed with PBS, fixed in 4% paraformaldehyde and 2% sucrose in PBS buffer pH 7.4, after 
which they were permeabilized using 1% glycine containing 0.02% Triton X-100 for 10 min 
at RT. Nonspecific binding sites were blocked with 1% BSA in PBS containing 0.05% Tween 
20 for 1 h at room temperature. Then, coverslips were incubated overnight at 4 °C with the 
primary antibodies for single or double staining (antibody concentration see table VIII). 
Coverslips were then washed and incubated with appropriate secondary antibodies (see table 
IX). Nuclei were visualized with 1μM Hoechst 333424 and TOTO-3-iodide 1:1,000 at RT 
embedded in Mowiol 4-88 with N-propyl gallate as an anti-fading agent. Images were 
captured using a confocal laser scanning microscope (Leica TCS SP2, Leica, Germany). 
Pictures were processed with Adobe Photoshop version 9.  
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2.2.15. Isolation of total RNA from fibroblasts  
The total RNA was isolated from control and IPF human lung fibroblasts as well as from 
transgenic mice TRII WT/KO, Smad3 WT/KO and TRI WT/CA fibroblasts by using the 
commercial RNAasy Minikit (QIAGEN, Hilden, Germany) and QIAshredder columns 
(QIAGEN, Hilden, Germany). Briefly, fibroblasts were plated in 12 mm cell culture dishes 
until they reached   70-80% confluency. Cells were rinsed with 1xPBS twice and lysed 
directly with RLT lysis buffer containing 1% β-mercaptoethanol. The homogenization was 
done by loading the cell lysate into a QIAshredder column. The homogenate was collected 
from the column by 2 min of centrifugation at 14,000x g and mixed with the same volume of 
70% ethanol in order to provide appropriate binding conditions prior to loading into the 
Rneasy Mini spin column. In the column, the total RNA was preferentially bound to the silica 
column. Contaminating DNA and proteins were removed by repeated sequential washes with 
appropriate buffers from the kit. Finally RNA was eluted from the column with RNAse free 
water. Samples were quantified with the Nanodrop spectrophotometer (Thermo Fisher 
Scientific, Waltham, Massachusetts, USA) and approximately 30 μg of RNA per sample was 
recovered and stored at -80°C until use. 
 
2.2.16. cDNA synthesis  
Total RNA was isolated using the Rneasy kit (Qiagen), and cDNA was synthesized by reverse 
transcription using the high-capacity iScript cDNA reverse transcription kit (Bio-Rad, 
Hercules, California, USA). To conduct the cDNA synthesis a reaction mix was prepared as 
shown in Table XIV. 
 
Components  Volume per 20 μl Reaction  
5x iScript reaction mix  4 μl  
iScript reverse transcriptase  1 μl  
Nuclease-free water  14 μl  
RNA template (1 μg/μl total RNA)  1 μl  
Table XIV. Reverse transcription reaction mix 
 
The reverse transcription reaction was conducted in a thermocycler (Thermo Fisher Scientific, 
Waltham, Massachusetts, USA), by employing the following program: 5 minutes incubation 
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at 25°C, 30 minutes at 42°C and 5 minutes at 74°C. The transcribed cDNA was stored at        
-20°C prior to further use. 
 
2.2.17. qRT-PCR 
Total RNA isolation of drug and cytokine treated fibroblasts and cDNA synthesis was done as 
described above. Quantitative RT-PCR analysis was carried out using the SYBR green premix 
on a qPCR machine (Bio-Rad iCycler) according to the manufacturer´s instructions. 
Normalization was done by using HPRT and 28S rRNA control primers for each template. 
Primers for quantitative RT-PCR analysis were designed by using Primer 3 Software. Each 
primer pair was tested for specificity and amplification efficiency by using gradient PCR, 
agarose gel electrophoresis and melting curve analysis. The relative expression, fold change 
of a defined gene was calculated using the ddCT method. PCR amplification of the cDNA 
was done with the above primers mentioned in the table X-XII. The exclusive amplification of 
the expected PCR product was confirmed by melting curve analysis.  
 
DNA amplification and the reaction mix is shown in Table XV. 
Content Amount  
Template, cDNA 0.15 μg (2 μl)  
SYBR Green  10 μl  
Primer(forward& reverse)  2 μl  
Water  6 μl  
Total  20 μl  
Table XV. qRT-PCR reaction mixture 
 
2.2.18. Semi-quantitative RT-PCR analysis  
For semi-quantitative analysis, specific primers for respective genes were designed using the 
PRIMER3 program (http://www.ncbi.nlm.nih.gov/tools/primer-blast) and synthesized by 
Eurofins, MWG or Operon (Ebersberg, Germany). Total RNA isolation of fibroblasts and 
cDNA synthesis was done as described above. Amplified PCR products were analyzed by gel 
electrophoresis using 1-2 % agarose gels. The PCR reaction was performed using 50 ng 
cDNA, 100 nmol forward and reverse primers and 1 μl 5PRIME TaqDNA polymerase 5 U/μl 
in a final volume of 25 μl.  
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2.2.19. Protein isolation from human control/IPF and mouse fibroblasts 
Proteins were extracted from human control and IPF fibroblasts as well as from TRII 
WT/KO, Smad3 WT/KO and TRI WT/CA (constitutively active) mouse fibroblasts with cell 
lysis buffer (1x) as described below with CompleteTM Protease inhibitor (Roche) added 
shortly before use (see table II). After mixing, 100 μl of cell lysis buffer was added to each 
well of the 12 well/plate. Fibroblasts were scraped thoroughly from the culture plate using a 
cell scraper and the lysate was pipetted into a 1.5 ml Eppendorf tube on ice. Cells were 
incubated for 20-min on ice with intermittent vortexing, cell debris and insoluble proteins 
were removed by centrifuging the cell lysate for 20 min at 10,000 g at 4 ºC. The supernatant 
was then transferred into a new 1.5 ml Eppendorf tube on ice and stored at -20 °C prior to 
further use. 
 
2.2.20. Protein isolation from mouse lung tissue 
Two g of tissue samples from TRII WT/KO, Smad3 WT/KO and TRI WT/CA mouse lungs 
were homogenized with a PotterǦElvehjem homogenizer at 1,000 rpm (1 stroke, 60 s) in 2 ml 
iceǦcold homogenization buffer (HMB) (see table II). The quality of the homogenization 
process was controlled by Trypan blue staining of the lung homogenates with a light 
microscope. Clumps of connective tissue, nuclei and large heavy mitochondria were 
sedimented by centrifugation of the homogenates at 2,500 × g for 20 min at 4°C. The total 
homogenate was processed for protein measurement. The protein concentrations of all 
fractions mentioned were assayed using a Bradford assay with BioǦRad solutions according to 
the manufacturer’s instructions. 
 
2.2.21. Measurement of protein concentration 
Briefly, the isolated protein solution was diluted 1:125 with water. To each sample and an 
additional blank control, 200 μl of Bio-Rad Bradford solution was added. Then, 4 μl of the 
protein sample or the buffer (same dilution) was added to each sample duplicates. This was 
followed by 15 min incubation period at RT. The absorption was read in a plate reader at 570 
nm. The concentration of the protein in each sample was calculated by using a newly prepared 
protein standard curve.  
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2.2.22. SDS-PAGE and Western blotting  
Control and IPF fibroblasts were washed with 1x PBS, lysed and the protein quantification 
done with the Bradford protein assay (Bio-Rad, Munich, Germany) as described above [159].  
Thirty μg of protein samples were separated by SDS-PAGE (12% gel) for ca. 2 h at 110 mV 
until the bromophenol blue marker reached the bottom of the gel. The gels with separated 
protein samples were further processed to blotting onto polyvinylidene difluoride membranes 
(PVDF, Millipore). Membranes were blocked with 5% skim milk or 5% BSA (depending on 
the following antibody steps), 50 mM Tris HCl (pH 7.6), 150 mM NaCl, and 0.05% Tween 
20 for 1 hr at RT or at 4 °C overnight. The primary antibodies were diluted in the appropriate 
blocking buffer, using dilutions described in table VIII, and incubated overnight at 4°C 
overnight.  On the following day, the membrane was washed three times 15 min in PBST. For 
secondary antibody detection, alkaline phosphatise-labelled goat anti-rabbit IgG or anti-
mouse IgG alkaline phosphatase (DPC Bierman) were used accordingly (see table IX).  
Antigen-antibody complexes were visualized with chemiluminescence detection using the 
Immun-Star alkaline phosphatase substrate from Bio-Rad according to the manufacturer’s 
instructions. The bands were visualized by exposing the blots to Kodak Biomax Films and 
quantified with a Bio-Rad Gel Doc 2000 system (Bio-Rad, Germany).  
 
2.2.23. Transfection and dual luciferase assay  
Control and IPF fibroblasts were cultured overnight. Transfection of plasmid DNA into the 
cells was performed by lipofection with TransIT-LT1 (Mirus Bio) as described previously 
[160] or Attractene transfection reagent as described in the manufacturer´s instructions 
(Qiagen). Cells were transfected with 1 μg of the firefly luciferase reporter plasmids in co-
transfection with 1μg of the indicated renilla luciferase expression vectors. Empty vector 
controls were run in parallel by using the appropriate empty vector plasmid in co-transfection 
experiments with the renilla luciferase expression vectors. Cells were transfected with 
plasmids and after 24 h treated with respective drugs and cytokines for indicated time-points. 
For the PPAR reporter assay, cells were cotransfected with PPAR-expression plasmid and 
the CIGNAL PPAR reporter construct and after 24 h treated with the respective cytokines and 
drugs for the indicated times as mentioned above. Cells were lysed with the luciferase lysis 
reagent (Promega), and firefly or renilla luciferase activities were determined with the 
appropriate substrates of the dual luciferase reporter assay system (Promega) as described in 
the manufacturer’s instructions.  
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2.2.24. Measurement of reactive oxygen species  
Generation of reactive oxygen species (ROS) was performed with dihydroethidine (DHE) at a 
final concentration of 5 μM. DHE is oxidized by superoxide to its fluorescent product 
ethidine. Ethidine is trapped intracellularly after it is oxidized, thus allowing quantitative 
estimations of the intracellular ROS level [161]. Control and IPF fibroblasts were grown on 
coverslips and transfected with PEX13 siRNA, control siRNA, or treated respectively with the 
above mentioned drugs and cytokines (see table III). DHE was added to the cells and 
incubated for 20 minutes. Thereafter cells were washed with 1x PBS and fixed with 4% 
paraformaldehyde in PBS, pH 7.4 for 20 minutes at RT. The coverslips were mounted for 
measuring cellular ethidine fluorescence under a confocal laser scanning microscope (Leica 
TCS SP2, Leica, Germany) (40X objective). Ethidine fluorescence intensity was quantified 
individually in all cells using the Leica Confocal Software program (Leica, Bensheim, 
Germany). One hundred cells per sample were evaluated. The measured values represent the 
mean fluorescence intensity (MFI) of ethidine per cell.  
 
2.2.25. Sircol Collagen Assay  
To examine the release of collagens into the cell culture medium, control and IPF fibroblasts 
were grown in 12 well plates for 24 hours, followed by PEX13 siRNA or control siRNA 
transfections using Interferin (4 μl or 2 μl). After 72 hours, the supernatants were collected 
and collagen production was analyzed by using the Sircol Assay protocol according to the 
manufacturer´s instructions (Biocolor).  
 
2.2.26. Cytokine ELISAs  
Control and IPF fibroblasts were transfected with PEX13 or control siRNA and 72 hours after 
transfection the supernatants were collected and levels of secreted cytokines were analysed 
using the human TGF- immunoassay, or the human IL-6 Quantikine ELISA Kit. In 
addition, cells were also treated with rHuTGF-, LY364947, ciprofibrate, GW6471 as 
mentioned above for 24 hours and the secreted levels of IL-6 were analyzed in the collected 
supernatants at the respective time-points with the Quantikine ELISA kit according to the 
manufacturer’s instructions. 
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2.2.27. Statistics 
All values are expressed as means ± SEM where n = 3 or 4. An unpaired Student’s t-test or 
ANOVA test using SPSS Software were used to assess the difference between two groups. 
Image J was used for quantification of RT-PCR expression. Differences were considered 
statistically significant when P<0.05.  
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3. Results 
The results of this thesis have been published in part in the Proceedings of the National 
Academy of Sciences of the United States of America (PNAS) and the pubmed ID of the 
following paper is: PMID: 25848047 
 
Oruqaj G, Karnati S, Vijayan V, Kotarkonda LK, Boateng E, Zhang W, Ruppert C, Günther 
A, Shi W, Baumgart-Vogt E. (2015). Compromised peroxisomes in idiopathic pulmonary 
fibrosis, a vicious cycle inducing a higher fibrotic response via TGF-β signaling. Proc Natl 
Acad Sci U S A. 2015 Apr 21;112(16):E2048-57. Doi: 10.1073/pnas.1415111112.  
 
3.1. General function of peroxisomes in maintaining oxidant/antioxidant 
balance and their implication in lung inflammatory conditions  
Oxidant and antioxidant imbalance in the lung is associated with various respiratory 
inflammatory diseases such as asthma, idiopathic pulmonary fibrosis, adult respiratory 
distress syndrome, COPD, pneumonia, lung transplantation and lung cancer [162-164]. 
Interestingly, peroxisomes are organelles that are intimately involved in ROS metabolism, 
since they contain various antioxidative enzymes such as catalase, and they are involved in 
the synthesis of polyunsaturated fatty acids and plasmalogens, which were suggest to trap 
ROS release [80, 112]. This thesis, was therefore based on the hypothesis that peroxisomal 
metabolism might be altered in the lung of IPF patients, and peroxisome induction would 
attenuate the fibrotic response, thus affecting the molecular pathogenesis of this devastating 
disease.  
 
3.2. Peroxisome biogenesis, lipid metabolism and redox balance are 
compromised in IPF patients 
First, lung samples of control subjects and IPF patients were analyzed for peroxisomal 
alterations. As mentioned above, catalase is the major peroxisomal antioxidative enzyme, 
therefore the first experiments were performed with anti-catalase antibodies on paraffin-
embedded lung tissue slices. Moreover, an anti-PEX14p antibody was used since this protein 
was described as the optimal marker to visualize peroxisomes [165]. Stainings of paraffin-
embedded tissue sections of human lung biopsies of controls and IPF patients revealed that 
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the peroxisomal number-as shown by PEX14p staining was reduced in fibroblasts in tissue 
sections of IPF lungs (Fig. 10). Moreover, catalase was strongly downregulated in fibroblasts 
of fibrotic areas of IPF lung samples (Fig. 10).   
 
 
Fig. 10. Peroxisomal proteins PEX14p and catalase were compromised in human lung biopsies of control 
and IPF tissues. Immunofluorescence for PEX14p and catalase (CAT) in control and IPF lung tissue. Negative 
control for the secondary antibody reaction with donkey anti-rabbit Alexa488 and donkey anti-mouse Alexa555. 
Co: control, IPF: idiopathic pulmonary fibrosis. RE (Respiratory epithelium), LP (Lamina propria), Arrows: 
fibroblasts in the lamina propria. Scale bar: 10 μm. 
 
Next, we analyzed whether isolated lung fibroblasts from these human IPF patients would 
retain the phenotype in cell culture. Indeed, these cells expressed higher levels of -SMA 
(Fig. 11A) and exhibited increased mRNA levels of the pro-fibrotic markers TGF-, 
COL1A2 and IL-6 (Fig. 11B) compared to the fibroblasts isolated from controls. The pro-
fibrotic phenotype was also confirmed by increased TGF-β signaling in IPF cells via 
luciferase reporter assay studies using an SBE-luciferase reporter plasmid (Fig. 11C).  
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Fig. 11. IPF fibroblasts retain their fibrotic phenotype in cell culture. (A) Single immunofluorescence of the 
fibrotic marker -SMA in control and IPF fibroblasts. (B) Expression of TGF-β1, Col1A2 and IL-6 mRNAs in 
control and IPF fibroblasts. (C) Luciferase reporter activity of SBE (Smad binding element) in control and IPF 
fibroblasts. The activity of firefly luciferase was measured in cell lysates and normalized to the activity of renilla
luciferase. E.V-empty vector. Co: control, IPF: idiopathic pulmonary fibrosis. Data represent means ± SD of 
three independent experiments. P value was calculated by unpaired Student t-test. Scale bar: 10 μm.
Analysis of protein abundance by immunofluorescence revealed that the peroxisomal 
biogenesis protein PEX13p and the metabolic proteins catalase, ACOX1 and ABCD3 were 
strongly reduced in IPF fibroblasts with retained pro-fibrotic phenotype, suggesting that 
peroxisomal functions in maintaining “redox balance and lipid metabolism” in IPF fibroblasts 
are disturbed (Fig. 12A-B). The downregulation of the peroxisomal biogenesis protein 
PEX13p was confirmed by Western blot (Fig. 12A). Similarly, a reduced expression of the 
PEX13 gene was observed at the mRNA level between control and IPF fibroblasts by qRT-
PCR analysis (Fig. 12A). Since, catalase (Fig. 12B) was downregulated, we hypothesized that 
IPF fibroblasts might have an impaired anti-oxidant response. DHE staining revealed that IPF 
fibroblasts exhibited a higher ROS production in comparison to control fibroblasts (Fig. 12D).
Downregulation of catalase and ACOX1 in IPF fibroblasts were also demonstrated at mRNA 
level (Fig. 12C). Interestingly, a series of anti-oxidative enzymes such as SOD1, heme 
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Downregulation of catalase and ACOX1 in IPF fibroblasts were also demonstrated at mRNA 
level (Fig. 12C). Interestingly, a series of anti-oxidative enzymes such as SOD1, heme 
oxygenase (HO-1), glutathione reductase (GR), and the redox sensitive transcription factor 
Nrf2 were also decreased in IPF fibroblasts (Fig. 13A-D). Moreover, reporter gene analyses 
showed that Nrf2 binding element (ARE)-driven luciferase activity was significantly 
decreased in IPF fibroblasts (5-fold reduction) (p<0.05) (Fig. 13E), whereas the luciferase 
activity of the AP1 reporter construct was not significantly changed in IPF fibroblasts in basal 
unstimulated conditions (Fig. 13E). Taken together, these results indicate that in IPF tissues as 
well as in IPF fibroblasts peroxisomal proteins were significantly downregulated and IPF 
fibroblast exhibit a disturbed antioxidant response.  
 
 
Fig. 12. Affected peroxisomal biogenesis, lipid metabolism and antioxidative response in IPF fibroblasts. 
(A) Expression of PEX13 at mRNA and protein level by immunofluorescence staining and Western blotting in 
both control and IPF fibroblasts. (B) Immunofluorescence staining of the peroxisomal proteins catalase, ACOX1 
and ABCD3 in control and IPF fibroblasts. (C) Expression of catalase and ACOX1 mRNAs in both control and 
IPF fibroblasts. (D) Generation of reactive oxygen species (ROS) detection with dihydroethidine (DHE) in 
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Fig. 13. Diminished antioxidative response in IPF fibroblasts. (A-D) Double immunofluorescence of the 
antioxidative enzymes SOD1, HO-1, GR and the redox-sensitive transcription factor Nrf2 together with the 
fibrotic marker -SMA in donor and IPF fibroblasts. (E) Luciferase reporter activity of ARE and AP1 promoter 
elements in control and IPF fibroblasts. The activity of firefly luciferase was measured in cell lysates and 
normalized to the activity of renilla luciferase. E.V-luciferase empty vector. SOD1: superoxide dismutase, HO-1: 
heme oxygenase-1, GR: glutathione reductase, Nrf2: nuclear factor erythroid 2–related factor 2. CO: Control, 
IPF: idiopathic pulmonary fibrosis. Data represent means ± SD of three independent experiments. P value 
calculated by unpaired Student t-test. Scale bar (A-D): 10 μm. 
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3.3. PEX13p knockdown activates Smad-dependent TGF- pathway and 
increases COL1 production 
Abrogation of peroxisomal proteins in IPF subjects may be a collateral effect due to persistent 
fibrosis or could also be a crucial factor that contributes to the pathogenesis of this devastating 
condition. To address this question, PEX13p, one of the peroxin proteins involved in 
peroxisomal biogenesis, was knocked down using a siRNA mediated approach. The strong 
knockdown of PEX13 expression in both control and IPF fibroblasts was verified by 
quantitative RT-PCR and Western blot analysis (Fig. 14A and B), and disruption of 
peroxisomal biogenesis, leading in consequence to mistargeting of catalase into the cytoplasm 
(Fig. 14C). Interestingly, disruption of the peroxisomal biogenesis triggered the production of 
the pro-fibrotic markers COL1A2 and TGF-at mRNA level and of the COL1 protein in 
Western blot analysis (Fig. 14A and B).  
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Fig. 14. Increased fibrotic response in PEX13 siRNA treated control and IPF fibroblasts. (A) RT-qPCR 
analysis of peroxisome biogenesis PEX13 and fibrotic markers TGF-β and COL1A2 in PEX13 siRNA 
transfected fibroblasts. The expressions of 28S rRNA and of the HPRT1 gene were used as controls for 
normalization, *p<0.005. (B) Western blots depicting the abundance of the peroxisomal biogenesis protein 
PEX13p and collagen I in PEX13 knockdown. The abundance of GAPDH was used as control. Sc (scrambled 
siRNA control), si-1 (siRNA PEX13-1), si-2 (siRNA PEX13-2), si-3 (siRNA PEX13 1 plus 2). (C) Mistargeting 
of the peroxisomal matrix enzyme catalase into the cytoplasm in control and IPF fibroblast due to the PEX13 
knockdown. Scale bar: 10 μm. Data represent means ± SD of three independent experiments. P value was 
calculated by unpaired Student t-test. 
 
The peroxisome deficiency was associated with increased TGF-in the culture medium and 
activation of TGF- signaling in fibroblasts shown by SBE luciferase reporter activation 
(Fig. 15A and B). Moreover, increased collagen levels were produced in the medium and the 
COL1A2 promoter activity was increased in the fibroblasts with PEX13 knockdown (Fig. 15C 
and D). It is noteworthy that also control fibroblasts exhibit an increased fibrotic phenotype 
after peroxisomal knockdown, even though to a lesser extent in comparison to the transfected 
IPF fibroblasts (Fig. 15A-D).  
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Fig. 15. Activation of TGF-β1 Smad pathway in PEX13 siRNA treated control and IPF fibroblasts.         
(A) TGF- release in supernatant measured by TGF-β1 ELISA. (B) SBE luciferase reporter assay in siRNA 
treated control and IPF fibroblasts. (C) Collagen Sircol assay, measuring the production of collagen released in 
the medium by control and IPF fibroblasts. (D) COL1A2 luciferase reporter assay in siRNA treated control and 
IPF fibroblasts. The activity of firefly luciferase was measured in cell lysates and normalized to the activity of 
renilla. E.V-empty vector. Sc (scrambled siRNA control), si-1 (siRNA PEX13-1), si-2 (siRNA PEX13-2), si-3 
(siRNA PEX13 1, 2). Data represent means ± SD of three independent experiments. P value was calculated by 
unpaired Student t-test. 
 
Additionally, PEX13 knockdown also led to the intracellular elevation of pro-fibrotic 
markers/proteins such as collagen I, collagen 3A1 (COL3A1) and prolyl 4-hydroxylase beta 
polypeptide (PDI) as revealed by immunofluorescence studies (Fig. 16A and B). Moreover, 
increased mRNA levels of matrix metalloproteinase 2 (MMP2) were detected in PEX13 
knockdown, an enzyme that has been implicated in excessive TGF- activation (Fig. 17A 
and E). The increased fibrotic response of TGF- and COL1A2 was also observed with semi-
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quantitative RT-PCR with a PEX13 knockdown in IPF fibroblasts (Fig. 17A-D). PEX13 
knockdown studies in control fibroblasts exhibited the same patterns as the ones of IPF (data 
not shown). To summarize, these results indicate that the downregulation of peroxisomes in 
both control and IPF fibroblasts leads to an increased fibrotic phenotype in these cells 
associated with an increased production of collagen and TGF- as well as an activation of 
TGF-β signaling. 
 
 
Fig. 16. Higher abundance of fibrotic marker proteins COL1, COL3A1 and PDI induced by the PEX13 
knockdown. (A-B) Depiction of the fibrotic marker proteins collagen I (COL1), collagen III (COL3A1) and 
prolyl 4-hydroxylase (PDI) by immunofluorescence staining in PEX13 knockdown control and IPF fibroblast 
cultures. Nuclei were stained with 1 μM Hoechst 33342. Scale bar: 10 μm. 
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Fig. 17. Increased fibrotic response and elevated MMP2 mRNA in PEX13 knockdown of IPF fibroblasts. 
(A) Expression of PEX13, TGF-1, COL1A2 and MMP2 at mRNA level shown by RT-PCR in IPF fibroblasts. 
Expression of 28S rRNA gene was used as control. (B-E) Quantification of mRNA expression from depicted 
genes in (A). BC: basal control, IC: interferin control, Sc: scrambled control, si-1: siRNA-1, si-2: siRNA-2. Data 
represent means ± SD of three independent experiments. P value was calculated by unpaired Student t-test.  
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3.4. Knockdown of peroxisomes leads to elevated ROS, increased ARE/AP1 
transcriptional activity and pro-inflammatory cytokines in fibroblasts 
As shown above in Fig. 12, IPF fibroblasts exhibit an increased production of ROS. Since 
peroxisomes are able to produce and scavenge ROS [80] and are downregulated in IPF 
fibroblasts, we questioned whether they are involved in the cellular ROS production observed. 
Indeed, the knockdown of PEX13 led to an increase in the production of ROS as measured by 
dihydroethidine staining both in control as well as IPF fibroblasts (Fig. 18A). However, 
unlike in the basal conditions of IPF fibroblasts (Fig. 13E), the acute downregulation of 
PEX13 increased ROS production, and was paralleled with increased ARE and AP-1 
promoter activity (Fig. 18B). Moreover, a high antioxidative response was induced leading to 
the upregulation of antioxidative enzymes such as HO-1, GR and abundance of the redox-
sensitive transcription factor Nrf2 (Fig. 19A and B). 
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Fig. 18. Induction of ROS and activation of ARE, AP1 transcriptional elements  in PEX13 knockdown 
control and IPF fibroblasts. (A) Detection of generated reactive oxygen species (ROS) with dihydroethidine 
(DHE) and quantification of the DHE staining in PEX13 siRNA-treated control and IPF fibroblasts, (N-number 
of cells for quantification). (B) ARE and AP-1 element luciferase reporter assays in PEX13 knockdown control 
and IPF fibroblasts, (si vs. Sc). (E.V-empty vector). The activity of firefly luciferase was measured in cell lysates 
and normalized to the activity of renilla. Sc (scrambled siRNA control), si-1 (siRNA PEX13-1), si-2 (siRNA 
PEX13-2). Data represent means ± SD of three independent experiments. P value was calculated by unpaired 
Student t-test. 
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Fig. 19. Antioxidative response in PEX13 siRNA treated fibroblasts. (A and B) Antioxidative response in 
PEX13 knockdown control and IPF fibroblasts, depicted by immunofluorescence staining for heme oxygenase-1 
(HO-1), glutathione reductase (GR) and Nrf2. BC: basal control, Sc: scrambled control, si: siRNA. Scale bar: 10 
μm.  
 
Next, we analyzed the effect of the PEX13 knockdown on the production of pro-inflammatory 
cytokines such as TNF- and IL-6, which have been proposed to play an important role in the 
pathogenesis of fibrosis. At the mRNA level both TNF- and IL-6 were significantly induced 
in PEX13 knockdown control and IPF fibroblasts in comparison to the respective cells 
transfected with the negative control siRNA (Fig. 20A). IL-6 was readily detectable and also 
significantly increased in the culture supernatants of PEX13 knockdown fibroblasts (Fig. 
20B). In contrast, by using the same supernatants under similar experimental conditions for a 
TNF-α ELISA, the concentration of this cytokine was too low for reliable detection (data not 
shown). In summary, knockdown of peroxisomes leads to increased ROS production and IL-6 
release in both control and IPF fibroblasts.  
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Fig. 20. Induction of cytokine production in PEX13 knockdown control and IPF fibroblasts. (A) qRT-PCR 
analysis of mRNA expression for cytokines (TNF-α and IL-6) in PEX13 knockdown of control and IPF 
fibroblasts. (B) Human IL-6 secretory levels measured by the Quantikine ELISA in PEX13 siRNA treated 
control and IPF fibroblasts. Sc (scrambled siRNA control), si-1 (PEX13-1 siRNA), si-2 (PEX13-2 siRNA), Data 
represent means ± SD of three independent experiments. P value was calculated by unpaired Student t-test. 
 
3.5. TGF-signaling downregulates peroxisomal biogenesis proteins in 
IPF fibroblasts 
By considering the pivotal role of TGF- in the pathogenesis of lung fibrosis, we thought to 
examine the possibility that it might modulate the expression of the PEX13 gene, and that 
activated TGF-signaling could account for impaired peroxisome biogenesis and metabolism 
in IPF. The fibrotic response of TGF-treatment was demonstrated by the upregulation of 
COL1A2 and IL-6 mRNAs, which were blocked specifically with the TGF- receptor 
inhibitor LY364947 (Fig. 21A). Elevated levels of IL-6 in culture supernatants of lung 
fibroblasts treated with TGF-and inhibition of the same cytokine with the TGF-receptor 
inhibitor LY364947 were confirmed by ELISA (Fig. 22A). Similarly, the activation of the 
TGF--Smad pathway in these cells was also confirmed by increased SBE luciferase reporter 
activity, increased TGF- mRNA (Fig. 22B and D, Fig. 21A) and by increased Smad3 
translocation into nucleus (Fig. 22C). We then analyzed whether the expression of the PEX13 
gene would be affected by TGF-stimulation. Interestingly, TGF- treatment indeed 
resulted in the downregulation of the PEX13 mRNA and protein, suggesting that TGF- 
inhibits peroxisomal biogenesis (Fig. 21B-C and 22D-E). This effect was reversed when 
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TGF- signaling was specifically blocked using the TGF-1 receptor inhibitor LY364947 
(Fig. 21B-C and 22D-E). TGF-1 treatment also increased ROS production in these 
fibroblasts (Fig. 21D).  
 
 
 
 
  
Fig. 21. TGF-β1 signaling suppresses the PEX13 mRNA expression and protein abundance in control/IPF 
fibroblasts. Confluent control and IPF fibroblasts were pretreated  with 5 μM LY364947 (TGF- inhibitor) for 
1 h,  followed by a stimulation with 5 ng/ml TGF-, or combined for 24 h. RNA expression of TGF-β1, 
COL1A2, IL-6 and PEX13 was examined by real-time qRT-PCR (A and B). The results were normalized with 
28S rRNA and HPRT mRNA.  (C) Total protein was isolated following 24 h incubation with TGF-β, LY364947 
or combinations and subjected to Western blotting for PEX13p. GAPDH was used as loading control. (D) 
Detection of TGF-β induced reactive oxygen species (ROS) with dihydroethidine (DHE) in control and IPF 
fibroblasts. C: control, T: TGF-β1, LY: LY364947, T + LY: TGF-β-1 + LY364947. Data represent means ± SD 
of three independent experiments. P value was calculated by unpaired Student t-test. 
D 
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Fig. 22. TGF- induction affects PEX13 in control and IPF fibroblasts. (A) IL-6 secretory levels measured 
by ELISA after treatment with TGF-1 (5 ng/ml) and LY364947 (5 μm) in control and IPF fibroblasts.             
C: control, T: TGF-β1, LY: LY364947, T+LY: TGF-β1 + LY364947 (B) SBE dual-luciferase reporter gene 
assay. The activity of firefly luciferase was measured in cell lysates and normalized to the one of renilla 
luciferase. Data represent the results of at least three experiments performed in triplicates. (C) Total Smad3 
protein staining of TGF-1 treated control and IPF fibroblasts. (D) Depiction of PEX13, TGF- and IL-6 
mRNA levels with RT-PCR, followed by quantification. Data represent means ± SD of three independent 
experiments. P value was calculated by unpaired Student t-test. Scale bar: 10 μm.  
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3.6. Downregulation of peroxisomal proteins in bleomycin-induced 
pulmonary fibrosis is abrogated in TRII bleomycin-treated knockout mice 
To extend and confirm these findings to the in vivo situation, lung mesenchyme-specific TGF-
β receptor II knockout mice were used. Since the anti-PEX13p antibody does not work 
properly for the staining of PFA-fixed paraffin-embedded tissue [165], an antibody against 
PEX14p, a binding partner of PEX13p in the docking complex of the peroxisomal membrane 
that was also reduced in IPF lungs (Fig. 1), was used. Indeed, bleomycin treatment in control 
mice downregulated peroxisomes (PEX14p) on day 7 after treatment, followed by a recovery 
on day 14 and 28 in comparison to day 7, however, upto a lower protein abundance than in 
appropriate control animals (Fig. 23). Strikingly, bleomycin treatment in TGF-β receptor II 
knockout mice did not induce the downregulation of peroxisomes as detected by staining with 
PEX14p, indicating a direct relation for TGF-β-induced signaling in the downregulation of 
peroxisomes (Fig. 23). Accordingly, also the downregulation of other peroxisomal enzymes 
such as ACOX1 and the antioxidative enzyme catalase on day 7 after bleomycin treatement 
were abrogated in TRII knockout mice, suggesting a possible link between TGF- signaling 
and regulation of peroxisomal metabolism (Fig. 24, 25). In summary, these findings indicate 
that TGF-1 signaling downregulates peroxisomes in bleomycin-induced pulmonary fibrosis, 
whereas abrogation of the TRII prevents the reduction of peroxisome abundance on the peak 
of inflammation on day 7 after bleomycin treatment, and so prevents the development of 
fibrosis. 
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Fig. 23. The reduction of PEX14p in the bleomycin-induced mouse model of lung fibrosis is abrogated by 
TRII knockout. Double immunofluorescence of PEX14p and -SMA in the bleomycin-induced mouse model 
of pulmonary fibrosis. Ctrl: Control, WT: wild-type, RII-KO: TGF-β receptor II knockout, Bleo: Bleomycin.  
Data represent the results of at least three reproducible experiments. Scale bar: 10 μm. 
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Fig. 24. The downregulation of ACOX1, a peroxisomal lipid metabolic enzyme in the bleomycin-induced 
mouse model of lung fibrosis is abrogated by the TRII knockout. Double immunofluorescence of Acyl-CoA 
oxidase 1 (ACOX1) and -SMA in bleomycin induced mouse model of pulmonary fibrosis. Ctrl: Control, WT: 
wild-type, RII-KO: TGF-β receptor II knockout (TRII), Bleo: Bleomycin. Data represent the results of at least 
three reproducible experiments. Scale bar: 10 μm. 
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Fig. 25. The downregulation of the peroxisomal antioxidative enzyme catalase in the bleomycin-induced 
mouse model of lung fibrosis is abrogated by the TRII knockout. Double immunofluorescence of catalase 
and -SMA in the bleomycin-induced mouse model of pulmonary fibrosis. Ctrl: Control, WT: wild-type, RII-
KO: TGF-β receptor II knockout (TRII), Bleo: Bleomycin. Data represent the results of at least three 
reproducible experiments. Scale bar: 10 μm. 
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3.7. AP-1 signaling is involved in TGF-1-mediated downregulation of 
PEX13 in human IPF fibroblasts 
Reports from literature indicate a cross-talk between TGF-β1 signaling and the transcriptional 
factor AP-1 [166]. In this study was also demonstrated an upregulation of AP-1 in PEX13 
knockdown fibroblasts [11]. Hence, we questioned if the transcriptional factor AP-1, normally 
activated during pro-fibrotic and pro-inflammatory responses, would also play a role in the 
observed TGF-1 mediated PEX13 downregulation. For a comparison, we also used the 
luciferase reporter vector (ARE) to test the activity of the ROS-activated transcriptional factor 
Nrf2. Indeed, stimulation with TGF-1 induced the activity of the AP-1 luciferase reporter 
construct (Fig. 26A) but the activity of the ARE-luciferase construct remained unchanged 
(Fig. 26B). Further, the AP-1 specific inhibitor SR11302 partially blocked the TGF-1 
stimulated activity of both the AP-1-luciferase construct and the ARE-luciferase construct 
(Fig. 26A, B). This was explainable, as the AP-1 binding element shares the consensus 
sequence of the Nrf2 binding element but not vice versa. The luciferase reporter assays 
revealed that the inhibitor luteolin used generally as Nrf2 inhibitor is not specific since it also 
inhibits the TGF--induced activation of AP-1 (Fig. 26A) in addition to the inhibition of 
ARE luciferase (Fig. 26B). Interestingly, pretreatment of cells with an AP-1 specific inhibitor 
SR11302 or the Nrf2/AP-1 inhibitor luteolin blocked the TGF--mediated SBE activation, 
indicating a role for AP-1 in the TGF-1-mediated Smad-dependent pathway (Fig. 26C). 
Moreover, pretreatment with SR11302 and luteolin also reversed the TGF-1-mediated 
downregulation of the PEX13p protein (Fig. 26D). To summarize, these findings suggest that 
the pro-fibrotic cytokine TGF-1 might downregulate PEX13 through the transcriptional 
factor AP-1. 
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Fig. 26. AP-1 signaling is activated in TGF-β1-mediated downregulation of PEX13 in human IPF 
fibroblasts. Confluent IPF fibroblasts were pretreated for 1 h with 25 μM luteolin or 10 μM SR11302 (SR). 
Then, cells were challenged with 5 ng/ml TGF-β for 24 h as indicated in the figure. (A-C) AP1, ARE and SBE 
luciferase reporter assays in IPF fibroblasts. The activity of firefly luciferase was measured in cell lysates and 
normalized to the activity of renilla luciferase. E.V-empty vector. (D) Protein analysis of PEX13p in IPF 
fibroblasts treated with TGF-β, luteolin or SR11302. GAPDH was used as loading control. Luteolin: Nrf2 
inhibitor, SR11302: AP-1 inhibitor. Data represent means ± SD of three independent experiments. P value was 
calculated by unpaired Student t-test.  
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3.8. Pro-inflammatory cytokines TNF-and IL-6 also suppress the 
peroxisome biogenesis protein PEX13p in human IPF fibroblasts 
In a complex disease condition such as IPF, factors other than TGF-1 may also contribute to 
the downregulation of peroxisomal genes in vivo. Macrophage-mediated TNF- production 
might play an important paracrine role in this process. To determine whether TNF- affects 
peroxisome biogenesis, IPF fibroblasts were treated with 10 ng/ml TNF- for the indicated 
time points (Fig. 27A and B). TNF- induced a significant downregulation of the PEX13 
mRNA as early as 1 h (Fig. 27A), as well as the protein abundance of PEX13p after 6 h (Fig. 
27B). Similar to TGF-β1, TNF-α also induced the activity of the AP-1 luciferase construct 
and increased the luciferase activity of the ARE-luciferase construct (Fig. 27C). Interestingly, 
the AP-1 inhibitor SR11302 reversed the TNF--mediated downregulation of PEX13p (Fig. 
27D). Finally, treatment with the pro-inflammatory cytokine IL-6 also induced the 
downregulation of PEX13p (Fig. 27E). In summary, pro-inflammatory cytokines (TNF-α and 
IL-6) downregulate PEX13p in IPF fibroblasts. Moreover, TNF-α-mediated downregulation 
of PEX13p is partially mediated through AP-1 signaling. 
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Fig. 27. TNF-α downregulates peroxisome biogenesis by induction of AP1 in human IPF fibroblasts.       
(A) IPF fibroblasts were treated with 10 ng/ml TNF- for the indicated time points, and the expression of PEX13 
mRNA was determined by using qRT-PCR. (B) IPF fibroblasts were treated with 10 ng/ml TNF-α for 6 h, and 
cells were lysed for Western blot analysis. As loading control GAPDH was used (C) ARE and AP-1 dual 
luciferase reporter assays of IPF fibroblasts treated with 10 ng/ml TNF-α for indicated times. The activity of 
firefly luciferase was measured in cell lysates and normalized to the activity of renilla luciferase. (D) IPF 
fibroblasts were treated with 10 ng/ml TNF-α for 6 h; cells were pretreated 1 h before with Nrf2 inhibitor 
Luteolin and AP-1 inhibitor SR11302 (SR), PEX13p abundance was analyzed with Western blotting. GAPDH 
was used as loading control (E) IPF fibroblasts were treated with 20 ng/ml IL-6 and PEX13p abundance was 
analyzed with Western blotting. GAPDH was used as loading control. E.V-empty vector. Data represent means  
± SD of three independent experiments.  P value was calculated by unpaired Student t-test.  
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3.9. PPAR-agonists proliferate peroxisomes and inhibit the TGF--
induced pro-fibrotic response in IPF fibroblasts 
As demonstrated above, reduced peroxisome biogenesis is associated with an increased pro-
fibrotic response as shown by the activation of TGF-1 signaling and collagen production. 
This raises the possibility that increasing the peroxisomal biogenesis may be beneficial as a 
treatment strategy in IPF. To evaluate the hypothesis we used two structurally distinct PPAR-
α agonists (ciprofibrate and WY14643), classical peroxisome proliferators, and investigated 
the relationship between peroxisome proliferation and TGF--induced myofibroblast 
differentiation (as shown by α-SMA abundance) and upregulation of the collagen I protein. 
Treatment with either ciprofibrate or WY14643 for 48 h resulted in proliferation of 
peroxisomes as detected by PEX14p staining (Fig. 28A). The peroxisomal biogenesis protein 
PEX13p was also induced after treatment of IPF cells with ciprofibrate or WY14643 (Fig. 
28B). PPAR-α has been shown to exert multiple effects on cellular targets which are 
independent of peroxisome proliferation, wherefore it is important to distinguish the 
peroxisome-dependent anti-fibrotic effects of PPAR-α agonists. To do this, the experimental 
setup (mentioned in detail in the methods) contained two different controls 1) IPF cells which 
were pretreated with PPAR-α agonists for 48 h after which the medium was replaced with the 
PPAR-α antagonist to block endogenous PPAR- α activation. Ideally, these cells then contain 
proliferated peroxisomes but further PPAR-α activation is blocked. 2) IPF cells which were 
pretreated with PPAR-α agonists only for 2 h prior to TGF-1 stimulation and hence will 
exhibit an activation of PPAR-α but no peroxisome proliferation due to the insufficiently 
short time period of drug treatment. The concentrations of PPAR-α agonists and antagonists 
that were used for this approach activated and inhibited the PPAR-response-element (PPRE)-
luciferase reporter construct respectively (Fig. 29A). Interestingly, IPF cells pretreated with 
ciprofibrate or WY14643 for 48 h showed a significant reduction in the TGF-β1-induced 
myofibroblast differentiation represented by the abundance of the -SMA protein. The 
strongest reduction was observed in the cells pretreated with PPAR-α agonist for 48 h 
followed by pretreatment with PPAR-α antagonist for 1 h prior to the addition of TGF-β1 
(Fig. 29B and 29C). Whereas, pretreatment with PPAR-α agonist for 2 h prior to TGF-β1 
stimulation did not block the TGF-1-induced -SMA protein. Similarly, the TGF-β1- 
induced COL1 protein was also blocked by the addition of the PPAR-α agonists (treated for 
48 h) followed by 1 h antagonist, but not in IPF cells solely pretreated with PPAR-α agonists 
for 2 h or 48 h (Fig. 29B, C). In summary, these findings suggest that in IPF cells with 
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proliferated peroxisomes the TGF-β1-induced upregulation of myofibroblast differentiation 
and the COL1 protein is blocked.  
 
 
 
 
 
 
 
 
 
 
Fig. 28. Peroxisome proliferation by PPAR-α agonists ciprofibrate and WY14643 in IPF fibroblasts.      
(A) Staining of IPF fibroblasts treated with ciprofibrate or WY14643 for 48h at the indicated concentrations with 
the peroxisomal marker PEX14p. (B) Western blot analysis of PEX13p in IPF cells treated with ciprofibrate or 
WY14643 for 48 h. CTRL: control, GW: GW6471, CIP: ciprofibrate, WY: WY14643. Data represent the results 
of at least three reproducible experiments. Scale bar: 10 μm. 
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Fig. 29. Peroxisome proliferation by PPAR-α agonists ciprofibrate and WY14643 blocks the TGF-β1-
induced pro-fibrotic response in IPF fibroblasts. (A) IPF cells co-transfected with PPAR-α expression 
plasmid (PPAR-α E.P.) and PPRE-luciferase-reporter vector (PPRE)/or empty vector (E.V) were treated with 
ciprofibrate (200 μM) or WY14643 (100 μM) or GW6471 (10 μM) for the indicated times after which the firefly 
luciferase activity was measured in cell lysates and normalized to the activity of renilla luciferase.                    
(B, C) Western blot analysis of IPF cells pretreated with WY14643 (100 μM) or ciprofibrate (200 μM) and/or 
GW6471 (10 μM) for the indicated times followed by treatment with TGF-β1 (5 ng/ml) for another 24 h. Note: 
After 48 h treatment of WY14643 or ciprofibrate, the medium was replaced with fresh serum free medium 
before stimulation with TGF-β1. Whereas, the medium was not replaced before the addition of TGF-β1 in cells 
pretreated with WY14643 or ciprofibrate for 2 h or GW6471 for 1 h. CTRL: control, GW: GW6471, CIP: 
ciprofibrate, WY: WY14643. Data represent the results of at least three reproducible experiments. Statistical 
analysis for luciferase assays were performed by ANOVA.  
 
 
 
A 
B 
C 
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3.10. Peroxisome proliferation by a PPAR-activator exerts a protective 
effect against the fibrotic response through suppression of ROS production 
and the inhibition of the IL-6 release 
As mentioned in the studies above, reduced peroxisome biogenesis is associated with 
increased TGF- activation and subsequently to ROS generation. Therefore, we investigated 
the relationship between ciprofibrate treatment, ROS and cytokine release and collagen 
production. Indeed, proliferation of peroxisomes and increase of PEX14p staining was 
observed after ciprofibrate treatment (Fig. 30A-B). Ciprofibrate also increased PEX13 mRNA 
expression (Fig. 30E). In contrast, COL1A2 expression was significantly reduced at the 
mRNA level upon ciprofibrate treatment (Fig. 30E). Consistent reduced ROS production (Fig. 
30A-C) and decreased IL-6 secretion were also detected upon ciprofibrate treatment (Fig. 
30D). Taken together, peroxisome proliferation by the PPAR- agonist exerts protective 
effects through diminishing ROS and reducing the IL-6 release.  
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Fig. 30. PPAR-agonist ciprofibrate induces peroxisome proliferation, decreases fibrotic markers COL1 
and reduces ROS and IL-6 levels in control and IPF fibroblasts. (A-B) Immunofluorescence for PEX14p of 
control and IPF fibroblasts treated with ciprofibrate at indicated concentrations and times. (A-C) ROS generation 
detected by DHE staining and its quantification.  (D) IL-6 production measured by ELISA as described above. 
(E) RT-PCR analysis for PEX13, COL1A2 mRNAs in ciprofibrate-treated control and IPF fibroblasts. Data 
represent means ± SD of three independent experiments.  P value was calculated by unpaired Student t-test. 
Scale bar: 10 μm. 
 
3.11. Peroxisome proliferation by a PPAR-activator inhibits cell 
proliferation in control and IPF fibroblasts 
 
Activation of PPAR- is reported to inhibit cardiac fibrosis through suppression of the ET-1 
pathway in vivo [167]. This inhibitory effects of fenofibrate may be caused by upregulation of  
p27Kip1 via suppression of c-jun expression and may be related to the cell cycle of cardiac 
fibroblasts [167]. Also in our study, we showed that ciprofibrate treatment significantly 
decreased the number of proliferating cells in both control and IPF fibroblasts (Fig. 31A-B). 
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Therefore, we speculated that this inhibition of proliferation might contribute to the 
alleviation of fibrosis progression by blocking fibroblast/myofibroblast differentiation.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 31. Peroxisome proliferation by PPAR- agonist ciprofibrate inhibits cell proliferation in control and 
IPF fibroblasts. Confluent control and IPF fibroblasts were treated with ciprofibrate with indicated 
concentrations and times. (A-B) Identification and quantification of fibroblast proliferation by Ki67 staining in 
control and IPF subjects. Data represent means ± SD of three independent experiments.  P value was calculated 
by unpaired Student t-test. Scale bar: 25 μm.  
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3.12. PPAR- inhibitor GW6471 blocks peroxisome proliferation and 
promotes myofibroblast differentiation as well as ROS release in control 
and IPF fibroblasts 
In order to further investigate whether the effects of ciprofibrate on reduction of the fibrotic 
response would be dependent on the PPAR-mediated proliferation of peroxisomes, the 
PPAR-antagonist GW6471 was applied in our study. Treatment of control and IPF 
fibroblasts with GW6471 for 24 h with two different concentrations (5 and 10 μM) increased 
the fibrotic response, shown by increased -SMA expression in control and IPF fibroblasts 
(Fig. 32A and B). Inhibition of peroxisome proliferation by GW6471 resulted in the increase 
of ROS production in both control and IPF fibroblasts (Fig. 32C). These results suggest that 
inhibition of the peroxisome proliferation and PPAR-by GW6471 would aggravate the 
fibrogenesis process in control and IPF fibroblasts.  
 
Fig. 32. PPAR-inhibitor GW6471 blocks peroxisome proliferation and increases profibrotic response. 
(A-B) Single immunofluorescence staining for PEX13 and -SMA in 24 h GW6471-treated control and IPF 
fibroblasts. Data represent the results of at least three experiments performed in triplicates. Scale bar: 10 μm 
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Fig. 33. PPAR- inhibitor GW6471 increases ROS generation in control and IPF fibroblasts. ROS 
quantification by DHE staining in 24 h GW6471-treated control and IPF fibroblasts. Data represent means ± SD 
of three independent experiments.  P value was calculated by unpaired Student t-test.  
  
 3.13. Upregulation of peroxisomal proteins in wild-type and TRII 
knockout mice  
In order to further investigate the role of TGF- signaling on peroxisome regulation, 
fibroblast cultures and lung tissue of TRII knockout mice were used to compare the 
peroxisomal compartment to corresponding wild-type littermates.  Consistent with the in vitro 
findings, the peroxisome biogenesis protein PEX13 as well as the peroxisomal lipid metabolic 
enzyme ACOX1 and antioxidative enzyme catalase were enormously upregulated in TRII 
knockout mice, in bronchial epithelium as well as in alveolar region of lung tissue as well as 
in lung fibroblasts isolated from mentioned subjects, suggesting a suppressing effect of    
TGF-signaling on peroxisomal proteins (Fig. 34A-B and 36A-B). The upregulation of 
peroxisomal proteins PEX13p and PEX14p were also shown by Western blot analysis      
(Fig. 35). 
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Fig. 34. Increased abundance of peroxisomal proteins in TRII knockout mice. (A-B) Double 
immunofluorescence staining for PEX13, ACOX1 and Catalase with -SMA in wild-type and TRII knockout 
lung tissue sections. Data is a representative of at least three reproducible experiments. Scale bar: 10 μm. 
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Fig. 35. Increased abundance of peroxisomal proteins in TRII knockout mice. Western blot analysis of 
PEX13p, PEX14p in wild-type and TRII knockout lung tissue. GAPDH was used as loading control. Data is a 
representative of at least three reproducible experiments. 
 
Similar alterations of peroxisomal proteins were also observed at the cellular level in cultures 
of isolated fibroblasts from wild-type and TRII knockout mice. A tremendous increase in the 
abundance of peroxisomal biogenesis proteins PEX13p and PEX14p was observed in TRII 
knockout fibroblasts (Fig. 36, Fig. 37). The TRII knockout was demonstrated by TRII 
staining and by Western blott in fibroblast culture (Fig. 36). The similar changes of increase 
in abundance of peroxisomal proteins were observed at mRNA level and by Western blot 
analysis in fibroblast cultures (Fig. 37). Since the TRII-KO is a mesenchymal specific 
knockout, the knockout of this receptor includes the majority of mesenchyme derived cells 
(Fig. 36). These findings strongly suggest that TGF- signaling might be involved in 
regulation of peroxisomal proteins, possibly by interacting with downstream transcription 
factors of TGF- Smad dependent and independent signaling.      
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Fig. 36. Upregulation of peroxisomal proteins in TRII knockout mice. (A) Double immunofluorescence 
staining of TRII with -SMA in wild-type and TRII knockout lung fibroblasts. (B) Western blot analysis for 
TRII, PEX13p and PEX14p in wild-type and TRII knockout lung fibroblasts. GAPDH was used as loading 
control. Data is a representative of at least three reproducible experiments. Scale bar: 10 μm. 
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Fig. 37. Upregulation of peroxisomal proteins in TRII knockout mice. (A) Double immunofluorescence 
staining of PEX14p with -SMA in wild-type and TRII knockout lung fibroblasts. (B) mRNA expression of 
PEX14 in TRII knockout mice was analysed with real time qRT-PCR. The results were normalized with 28S 
rRNA and HPRT mRNA.  Data is a representative of at least three reproducible experiments. Data represent 
means ± SD of three independent experiments.  P value was calculated by unpaired Student t-test. Scale bar: 10 
μm. 
 
3.14. Upregulation of peroxisomal proteins in wild-type and Smad3 
knockout mice  
In order to investigate the possible regulation of peroxisomal proteins by TGF- signaling, 
and in particular by TGF- Smad-dependent pathway, general Smad3 knockout mice were 
used. Similar to mice with completely disturbed TRII signaling, Smad3 knockout mice 
exhibited an increased abundance of the peroxisomal proteins involved in organelle 
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biogenesis (PEX14p), peroxisomal lipid metabolism (ABCD3, ACOX1) as well as 
peroxisomal antioxidative response (catalase) (Fig. 38A and 39A-B). Similar changes of the 
peroxisomal biogenesis protein PEX13p and the antioxidative enzyme catalase were observed 
with Western blot analysis (Fig. 38B). The Smad3-KO was verified by using an anti-Smad3 
antibody (Fig. 38B).  
 
 
Fig. 38. Upregulation of peroxisomal proteins in Smad3 knockout mice. (A) Double immunofluorescence 
staining of PEX14p with -SMA in wild-type and Smad3 knockout lung tissue sections. (B) Western blot 
analysis of Smad3, PEX13p and catalase in wild-type and Smad3 knockout lung tissue. GAPDH was used as 
loading control. Data is a representative of at least three reproducible experiments. Scale bar: 10 μm 
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Fig. 39. Upregulation of peroxisomal proteins in Smad3 knockout mice. (A-B) Double immunofluorescence 
staining of ABCD3, ACOX1 and Catalase with -SMA in wild-type and Smad3 knockout lung tissue sections. 
Data is a representative of at least three reproducible experiments. Scale bar: 10 μm. 
 
To confirm, that the TGF- regulation of peroxisomal proteins also occurs in primary cell 
culture, fibroblasts were isolated from wild-type and Smad3 knockout mice mouse lungs. 
Indeed, the expression of peroxisomal biogenesis protein PEX13p was similarly upregulated 
in Smad3 knockout fibroblasts as shown by Western blot analysis (Fig. 40). Moreover, the 
mRNA levels for PEX14 and catalase were upregulated in Smad3 knockout fibroblasts (Fig. 
40). The increase of PEX13p abundance in the Western blots corroborates the morphological 
results obtained in Smad3-KO lungs and coincides with the downregulation of collagen I (Fig. 
40).  
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Fig. 40. Upregulation of the peroxisomal biogenesis protein PEX13p in Smad3 knockout mouse lung 
fibroblasts. (A) mRNA expression of PEX14 and catalase in Smad3  knockout mice was analysed with real time 
qRT-PCR. The results normalized with 28S rRNA and HPRT mRNA. (B) Western blot analysis of PEX13p and 
collagen I in wild-type and Smad3 knockout mice lung fibroblasts. GAPDH was used as loading control. Data 
represent means of ± SD of three independent experiments. P value was calculated with unpaired Student t-test. 
 
3.15. Upregulation of TGF- signaling via constitutively active TR-I 
activation leads to reduction of peroxisomal biogenesis in the lung of one 
month old mice  
The TGF-beta receptor I (TRI) is crucial in activation of Smad-dependent regulation of gene 
transcription. Therefore, a transgenic mouse expressing a constitutively active TGF- type I 
receptor (TRI/ALK5) was used to investigate the Smad-dependent regulation of the 
peroxisomal biogenesis protein PEX14p. TRICA is c-myc tagged at the C-terminal end to be 
able to assess the TGF- receptor I overexpression. The peroxisomal biogenesis protein 
PEX14p was strongly downregulated in the lung of one-month-old mice in cells 
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overexpressing the TRICA as shown by immunocytochemistry staining (Fig. 41). The 
downregulation of PEX14p was also observed by Western blot analysis in lung homogenates 
of one-month-old TRICA mice, whereas in lung homogenates of 3-month-old animals TR-I 
activation upregulated the peroxisomal biogenesis protein PEX14p (Fig. 42). Taken together, 
TGF- participates in regulation of peroxisomal biogenesis proteins possibly via Smad-
dependent signaling.  
 
 
Fig. 41. Downregulation of peroxisomal biogenesis protein PEX14p in TRI constitutively active mice. 
Immunochemistry staining of lung tissue paraffin sections from one-month-old wild-type and TRICA mice.    
(A-B) IHC staining for the c-myc-tagged TRI revealed the higher abundance of this receptor in the TRICA 
mice. (C-F) PEX14p staining was strongly downregulated in lung tissue of mice with TGF- receptor I 
overexpression in bronchioli and the alveolar region in comparison to wild-type animals. TRI WT: TGF- 
receptor 1 wild-type, TRICA: TGF- receptor I constitutively active. Data is a representative of at least three 
reproducible experiments. Scale bar: 10 μm. 
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Fig. 42. Alterations of peroxisomal biogenesis protein PEX14p in TRICA mice. Western blot analysis of 
PEX13p and collagen 1 in wild-type and TRICA mouse lung tissue homogenates of 1- month and 3-month-old 
animals. GAPDH was used as loading control. TRI WT: TGF- receptor 1 wild-type, TRICA: TGF- receptor 
1 constitutively active, 1M: 1-month, 3M: 3-month. Data is a representative of at least three reproducible 
experiments. 
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4. Discussion  
The findings demonstrated in this thesis revealed a novel mechansism and provide compelling 
evidence that peroxisomes are protective organelles against the development or progression of 
lung fibrosis by scavenging ROS and participating in metabolism of lipid mediators, thus 
inhibiting the release of cytokines that trigger TGF- signaling. Importantly, it was 
demonstrated that in lung tissue samples of IPF patients as well as in IPF fibroblast cultures 
peroxisomal proteins are downregulated. Furthermore, siRNA-mediated downregulation of 
the peroxisomal biogenesis protein PEX13p elicits a pro-fibrotic response, via activation of 
TGF- signaling. Accordingly, treatment of IPF fibroblasts with PPAR-α agonists such as 
ciprofibrate or WY1463 increased the peroxisomal abundance and decreased the TGF-β1- 
induced myofibroblast differentiation. The findings also indicate that dysfunctional 
peroxisomes lead to increased cellular ROS production in IPF cells. Most importantly, in vivo 
findings in our bleomycin-induced TβRII knockout mouse model studies, loss of TGF-β 
signaling prevented the bleomycin-induced downregulation of peroxisomal proteins such as 
PEX14p, ACOX1 and catalase. As demonstrated in this thesis, downregulation of 
peroxisomes is mediated via TGF- signaling, a pivotal cytokine important in pathogenesis of 
IPF and a crucial regulator of peroxisome biogenesis and metabolism.  
 
4.1. Role of peroxisomes in maintaining oxidant/antioxidant balance and 
their implication in lung inflammatory conditions and idiopathic 
pulmonary fibrosis 
It is well known that the lung is one of the organs most exposed to the various forms of 
reactive oxygen species due to its high oxygen environment [113]. Oxidant and antioxidant 
imbalance in the lung is associated with various respiratory inflammatory diseases such as 
asthma, idiopathic pulmonary fibrosis, adult respiratory distress syndrome, COPD, 
pneumonia, lung transplantation and lung cancer [162-164]. Especially, lung inflammatory 
diseases such as asthma and COPD as well as IPF as restrictive pulmonary disease are 
characterized by elevated reactive oxygen species (ROS) released from inflammatory cells, 
and oxidative stress plays an important role in the pathogenesis of these diseases [11, 164]. 
Moreover, scavenging or diminishing ROS was demonstrated also to protect mice from 
bleomycin-induced lung fibrosis [83]. Peroxisomes are present in different pulmonary cell 
types and exhibit strong heterogeneity in their abundance and enzyme composition [80]. 
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Peroxisomes produce high amounts of hydrogen peroxide, but also possess the most efficient 
antioxidative enzyme catalase, which scavenges hydrogen peroxide, thus helping to maintain 
the cellular oxidant/antioxidant balance [168]. Catalase as an important peroxisomal 
antioxidative enzyme was diminished in idiopathic pulmonary fibrosis as well as inhibited in 
bleomycin-induced pulmonary fibrosis, suggesting a protective role against inflammation and 
the development of lung fibrosis [11, 169]. Interestingly, ROS production is enormously 
increased in cases of downregulation of the antioxidative enzymes such as catalase and 
MnSOD in airway smooth muscle (ASM) [170]. In this respect, the protective role of 
peroxisomes in pulmonary fibrosis is closely associated with their functions in scavenging 
ROS species thus preventing excessive ROS generation and subsequent inflammatory 
reactions [5, 80, 120]. Accordingly, our findings also indicate that dysfunctional peroxisomes 
lead to increased cellular ROS production in IPF cells. This is in concordance with previous 
studies showing that the deficiency of peroxisomal proteins leads to increased ROS 
production and oxidative stress [114, 171].  
 
4.2. TGF-1 is a crucial pathogenic factor in development of IPF and ROS 
induction, and an important regulator of peroxisome biogenesis and 
metabolism 
In this respect, TGF-1 is thought to be a crucial pathogenic factor for the development of IPF 
by inducing epithelial cell death, ROS production and consequently deposition of 
extracellular matrix production and foci formation [82, 83, 85, 172]. Moreover, TGF- a 
key cytokine in proinflammatory and fibrotic processes is found to be upregulated in airway 
smooth muscle (ASM) in patients with asthma and COPD, as well as in lung fibroblasts of 
patients with idiopathic pulmonary fibrosis [11, 170]. In addition, TGF- also triggers ROS 
release through NADPH oxidases or direct activation of NADPH oxidase 4 (Nox4) by other 
mechanisms, induces enormous ROS generation in airway smooth muscle of asthma patients 
as well as in myofibroblasts of IPF patients [5, 170]. In this thesis is demonstrated the role of 
peroxisomal proteins in attenuating the fibrotic response, and in particular the impact of TGF-
 signaling on regulation of peroxisome biogenesis and metabolim. It is of particular interest 
to emphasize that in the observed findings lung tissue samples as well as fibroblasts of IPF 
patients exhibit reduced peroxisomal protein abundance, mimicking some molecular 
pathogenic mechanisms of Zellweger syndrome, a peroxisomal disorder with complete 
absence or reduced number of peroxisomes, and progressive development of hepatic fibrosis 
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[115]. We hypothesized that a continuous trigger would be necessary to induce this consistent 
downregulation of peroxisomes in IPF fibroblast cultures since peroxisomal biogenesis would 
complement for this downregulation over time. Based on our findings that the SBE-luciferase 
activity was higher in IPF cells in their basal state and contained increased concentrations of 
TGF-β1 in the cell culture medium (Fig. 11C and 15A), we propose that the persistent 
activation of TGF-β signaling in these cells might be responsible for the downregulation of 
peroxisomal proteins in IPF subjects. This hypothesis is also supported by the in vivo findings 
in our bleomycin-induced TβRII knockout mouse model studies, in which loss of TGF-β 
signaling prevented the bleomycin-induced downregulation of peroxisomal proteins such as 
PEX14p, ACOX1 and catalase (Fig. 23, 24, 25). In addition, peroxisomal proteins were 
strongly upregulated in TRII knockout mice and Smad3 knockout mice, indicating a 
suppressive effect of TGF- signaling on peroxisomal metabolism. Since the TRII knockout 
mice are mesenchymal specific knockout and no general KO mice, the majority of 
mesenchyme-derived cells contain the knockout such as fibroblasts, therefore few other cell 
types exhibit a slight expression of TRII in the knockout animals.  Consistent with these 
findings, TRI constitutively active mice (TRICA) inducing continuous TGF-signaling 
activation exhibit a reduced abundance of the peroxisomal biogenesis protein PEX14p in 1-
month-old mice. The upregulation of peroxisomes in lung samples of 3-month-old mice in 
TRICA suggests the involvement of compensatory mechanisms regulating the peroxisome-
related gene expression, under continuous stress conditions to escape from the acute 
suppressive effect of TGF- signaling. To our knowledge, this is the first study to show a 
direct role of TGF-β signaling in the regulation of peroxisome-related genes, possibly by 
interacting with downstream transcription factors of TGF-signaling (e.g. Smad3, Smad4).  
 
4.3. Pro-inflammatory cytokines TNF-and IL-6 inhibit the peroxisome 
biogenesis protein PEX13p via AP-1 signaling  
Furthermore, downregulation of the peroxisomal genes by the pro-inflammatory cytokine 
TNF- has been shown previously in the liver [133]. In this thesis, we extended our 
knowledge on the molecular mechanisms leading to the TNF- mediated downregulation of 
peroxisomes by showing that TNF- mediates this effect through activation of AP-1 (Fig. 
27C-D). It is known that TNF--/- mice develop less liver fibrosis in comparison to littermate 
controls, exhibit reduced levels of -SMA, a marker for activated myofibroblasts, and 
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reduced TGF-1 mRNA [173]. Consistent with our findings are the existing evidences from 
the literature that TNF- is crucial in initiation and progression of the fibrotic processes via 
AP-1 in Swiss 3T3 fibroblasts [99, 101]. Similarly, the interplay between Smad-dependent 
TGF-β signaling and AP-1 that we observed in our study [11] has also been reported in 
numerous studies and are still contradictory. In one study, the transcriptional factor AP-1 was 
reported to be essential for ROS-mediated TGF-β1 activation and TGF-β1-induced IL-6 
production [174] which is in line with our finding that AP-1 signaling activates Smad-
dependent SBE activation (Fig. 26C) [11]. In contrast to this, Verrecchia and colleagues 
reported that the Jun family of AP-1 factors acts as inhibitor of Smad-dependent signaling 
[166]. The AP-1 family of transcriptional factors is a broad class of transcriptional factors that 
can form hetero and homo dimmers and were shown to be both pro-fibrotic and anti-fibrotic, 
based on the specific factors activated in different conditions [175, 176]. Further studies to 
specifically identify the AP-1 factors activated due to peroxisomal dysfunction are required to 
understand this observed pro-fibrotic nature in our experimental conditions. In addition to 
TNF- also other proinflammatory cytokines were reported to play a role in the molecular 
pathogenesis of lung fibrosis [5, 177]. In agreement with this notion are the findings of this 
thesis that PEX13 knockdown in fibroblasts induces activation of TGF-β signaling, increased 
ROS, collagen and IL-6 production. Several studies have reported that ROS and the release of 
pro-inflammatory cytokines are the main triggers of TGF- signaling pathway, shown also in 
bleomycin-induced lung fibrosis mouse model at the peak of inflammation on day 7 [5, 177]. 
Interestingly, in our bleomycin model the strongest downregulation of peroxisomes was also 
observed at day 7 (Fig. 23), which is consistent with our in vitro findings that pro-
inflammatory cytokines TNF-α and IL-6 downregulate peroxisomes in IPF fibroblasts (Fig. 
27D-E).  IL-6 is known to mediate many inflammatory processes in the lung and has been 
implicated in the pathogenesis of a variety of respiratory disorders and the possible 
association between IL-6 and development of fibrosis was described [178, 179]. In addition, 
IL-6 plays an important role in development of BLM-induced lung inflammation and 
subsequent fibrotic changes through the activation of TGF signaling [104]. ROS interferes 
with many cellular functions and results in activation of the master regulators of the cellular 
response to oxidative stress such as Nrf2 and NF-B and the induction of the anti-oxidative 
machinery [180]. Although we were able to identify the activation of Nrf2 in our PEX13 
knockdown fibroblasts based on the ARE-luciferase activity, luteolin which is commonly used 
in studies as an Nrf2 inhibitor was also found to inhibit the transcriptional factor AP-1. Hence 
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at present we cannot conclude that the observed effect of luteolin on SBE activation is solely 
dependent on its ability as an Nrf2 inhibitor.  
 
4.4. Proliferation of peroxisomes by PPAR-agonists inhibit the TGF--
induced pro-fibrotic response, myofibroblast differentiation and fibroblast 
proliferation 
Finally, we also show that pretreatment of IPF cells with PPAR-agonists for longer time-
points reduced the TGF-β1-induced collagen and myofibroblast differentiation, provided that 
the endogenous PPAR-α activation during TGF-β1 stimulation is blocked. This is particularly 
interesting because several independent studies that reported anti-fibrotic effects of PPAR-α 
agonists have not considered peroxisome proliferation by these agonists. This is largely due to 
the vast amount of accumulating evidence in the literature describing the broad anti-fibrotic 
and anti-inflammatory properties of PPAR-. In particular are the studies which report that 
PPAR agonists i) prevent cardiac fibrosis by inhibiting the proliferation of cardiac 
fibroblasts through suppression of ET-1 pathway [167], ii) reduced the lung injury induced by 
bleomycin [155] andiii) inhibit TGF- induced transcription of 5 integrin in vascular 
smooth muscle cells [181]. The inhibiting effects of fenofibrate on cardiac fibroblast 
proliferation may be caused by upregulation of  p27Kip1 by suppression of c-jun expression 
and may be related to the cell cycle of cardiac fibroblasts [167]. Consistent with this study 
above, ciprofibrate inhibits fibroblast proliferation in control and IPF fibroblasts. 
Furthermore, PPAR- as a transcription factor mediates peroxisome proliferation in rodent 
liver, and a functional PPRE is found about 8.4 kb downstream of the PEX11 promoter 
[119], encoding a protein involved in peroxisome proliferation [119, 132]. Lack of specific 
and potent peroxisome proliferators that are independent of specific PPAR-activation is one 
of the main technical limitations in distinguishing the beneficial effects of peroxisome 
proliferation. Although the findings presented here suggest that peroxisome proliferation 
rather than the endogenous PPAR-α activation mediates the anti-fibrotic effects observed, we 
cannot rule out the possibility of other molecular targets being altered during this 48 h 
pretreatment with PPAR-α agonists. Similarly, it should also be taken into consideration that 
the PPAR-α antagonist, GW6471 used in this study might also interfere in the 
activation/regulation of other PPAR family members, leading to secondary effects, which 
could result in the inhibitory effect observed on TGF--induced α-SMA and collagen. Future 
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studies have to be carried out to confirm the specificity of this PPAR-α antagonist and to get 
more insights into the complex interactions of distinct PPARs on the PPREs of dependent 
genes, e.g. genes for peroxisomal proteins. Our study also highlights the necessity to design 
and synthesize new drugs with selective peroxisome proliferation activity, independent of 
PPARs, to resolve the technical difficulties in studying the beneficial effects of peroxisome 
proliferation in disease models. 
 
4.5. Concluding remarks 
Taken together, activation of TGF- signaling during lung injury and subsequent induction 
and release of pro-inflammatory mediators such as TNF-α, ROS and IL-6 in IPF, leads to the 
downregulation of peroxisomes (e.g. PEX13) via AP-1 transcription factor, thus enabling the 
persistence of a fibrotic phenotype, which in turn generates more ROS and elevates secretion 
of proinflammatory cytokines (e.g. IL-6) (Fig. 43). Moreover, the activation of TGF-β 
signaling (Smad-dependent pathway) in peroxisome downregulation through PEX13 
knockdown promotes the increase of extracellular matrix production and generation of a 
fibrotic phenotype (Fig. 43).  In summary, this study identifies a functionally relevant and 
potentially possible target for future development of new viable therapeutic approaches “the 
peroxisome”, and significantly extends the role of this organelle in the maintenance of normal 
cellular function by scavenging ROS, metabolizing lipid mediators, and by protecting against 
inflammatory processes, leading eventually to exacerbations in patients with pulmonary 
fibrosis. 
 
 
 
 
 
 
 
 
 
93 
 
 
Fig. 43. Mechanism: Schematic illustration of TGF-β1 effects on peroxisome function, described as 
proposed model in this study. In idiopathic pulmonary fibrosis, lung injury leads to the production of pro-
inflammatory mediators such as TNF-α, IL-6 and ROS and the activation of pro-fibrogenic TGF-β-and AP-1 
signaling. This leads to downregulation of peroxisomes (e.g. PEX13p), which in turn induces more ROS, 
promotes secretion of cytokines such as IL-6 and triggers the activation of TGF-βand AP-1 signaling in a 
vicious cycle thus enabling the persistence of a fibrotic phenotype and inflammatory exacerbation phases in IPF 
patients. In addition, this vicious cycle also leads to increased production of collagen. In contrast, treatment with 
PPAR-α agonists induce the proliferation of peroxisomes and inhibit the pro-fibrogenic mechanisms such as 
myofibroblast differentiation (α-SMA) and collagen release [11]. 
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5. Summary 
Idiopathic pulmonary fibrosis (IPF) is a chronic devastating disease, and its pathogenic 
mechanisms remain incompletely understood. In this disease, the lung undergoes dramatic 
pathological remodelling and myofibroblasts with high α-smooth muscle actin (α-SMA) 
content secrete huge amounts of extracellular matrix. However, altered peroxisome functions 
in IPF pathogenesis have never been investigated. Proinflammatory mediators and reactive 
oxygen species (ROS) accumulation were shown as pathogenetic mechanisms of this yet 
incurable disease. Since peroxisomes are involoved in both the degradation of 
proinflammatory lipid mediators (eicosanoids) as well as ROS metabolism, alterations in the 
protective capacity of this organelle might contribute to the pathogenesis of IPF. In addition, 
children with Zellweger Syndrome, the most severe peroxisomal biogenesis defect, develop 
chronic liver fibrosis and cirrhosis, suggesting that the peroxisomal metabolism is essential 
for the protection against fibrotic organ degeneration. In the experimental part of this thesis 
the hypothesis was tested, 1) whether the peroxisomal compartment and corresponding gene 
expression is altered in IPF, 2) whether the downregulation of peroxisomal biogenesis and 
metabolism in IPF promotes further excessive secretion of extracellular matrix proteins and 
proinflammatory mediators and 3) whether proinflammatory and profibrotic cytokines 
influence peroxisomal abundance and metabolism. Moreover, the molecular mechanisms 
leading to the alterations of the peroxisomal compartment were investigated. In addition, a 
bleomycin induced lung fibrosis mouse model was used to analyze peroxisomal biogenesis, 
antioxidative and lipid metabolic proteins at various time-points after bleomycin treatment. 
The molecular mechanisms and specific involvement of peroxisomal proteins in TGF- 
induced ECM production were investigated. Finally the effect of TGF-1 on the peroxisomal 
compartment in TGF-beta receptor II knockout (TRII) and Smad3 knockout mice as well in 
transgenic constitutively active TRICA overexpressing mice was studied. In this thesis, the 
peroxisomal compartment as well as peroxisomal metabolic proteins were analyzed in parallel 
to several cell type-specific markers in paraffin sections of different lung tissue samples of 
human controls in comparison to IPF patients. In addition, primary cultures of lung fibroblasts 
of the same individuals were used for morphological, biochemical and molecular biological 
analysis of peroxisomal protein alterations. Moreover, control and IPF fibroblast were 
challenged with TGF-TNF-, IL and PEX13 siRNA to analyze the impact of 
peroxisomes on the molecular pathogenesis of IPF. To confirm this in vitro findings the 
bleomycin induced lung fibrosis mouse model and TRII mice were used to study peroxisome 
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biogenesis and metabolism in situ in these animal models. By comparing peroxisome-related 
protein and gene expression in lung tissue and isolated lung fibroblasts between human 
control and IPF patients, we found that IPF lungs exhibited a significant down-regulation of 
peroxisomal biogenesis and metabolism (e.g. PEX13p, catalase, ABCD3 and acyl-CoA 
oxidase 1). Moreover, in vivo the bleomycin-induced downregulation of peroxisomes was 
abrogated in TRII mice indicating a role for TGF-βsignaling in the regulation of 
peroxisomes. Furthermore, in vitro treatment of IPF fibroblasts with the pro-fibrotic factors 
TGF-β1 or TNF-α was found to downregulate peroxisomes via the AP-1 signaling pathway. 
Therefore, the molecular mechanisms by which reduced peroxisomal functions contribute to 
enhanced fibrosis were further studied. Direct down-regulation of PEX13 mRNA by RNAi   
1) induced the activation of Smad-dependent TGF-β signaling, accompanied by increased 
ROS production, 2) resulted in the release of cytokines (e.g. IL-6, TGF-β) and excessive 
production of collagen I and III. In contrast, treatment of fibroblasts with ciprofibrate or 
WY14643, PPAR-α activators, induced peroxisome proliferation and reduced the TGF-β-
induced myofibroblast differentiation and collagen protein in IPF cells. 
Overall in this thesis it could be proven that the peroxisomal compartment is severely affected 
and compromised in IPF, mediated by TGF-1 signaling and the action of proinflammatory 
cytokines (TNF- and IL-6) via AP-1 signal transduction. TGF- downregulates 
peroxisomes via the Smad-dependent pathway, which results in reduced ability of cells to 
scavenge ROS, degrade proinflammatory lipid mediators (eicosanoids) and subsequently 
inducing a vicious cycle, leading to the aggravation of IPF. Thus, TGF- and TNF- may 
exacerbate the clinical conditions and intensify the fibrotic response in patients with IPF upon 
inflammation and lung injury by the downregulation of peroxisomal biogenesis and 
metabolism (e.g. PEX13, ACOX1).  
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6. Zusammenfassung  
Die Ideopathische Lungenfibrose (IPF) ist eine schwerwiegende chronische 
Lungenerkrankung, deren Pathomechanismus bis heute noch nicht vollständig aufgeklärt 
wurde. Im Verlauf dieser Erkrankung wird die Lungenstruktur dramatisch pathologisch 
umgebaut und Myofibroblasten mit einem hohen Gehalt an -glatten Muskelzellaktin          
(α-SMA) sezernieren riesige Mengen extrazelluläre Matrix. Die Ansammlung von 
proinflammatorischen Mediatoren und reaktiven Sauerstoffspezies (ROS) ist bisher als 
pathogener Faktor dieser nach wie vor unheilbaren Krankheit, nachgewiesen worden. Da 
Peroxisomen sowohl in den Abbau von proinflammatorischen Lipidmediatoren (Eicosanoide) 
als auch in den ROS-Stoffwechsel eingebunden sind, könnten Veränderungen der 
peroxisomalen Schutzfunktion zur molekularen Pathogenese der IPF beitragen. Weiterhin 
entwickeln Kinder mit Zellweger Syndrom, den schwersten Phänotyps der peroxisomalen 
Biogenese Defekte (PBD), chronische Leberfibrose bzw. Zirrhose, was für die essentielle 
Bedeutung des peroxisomalen Stoffwechsels zum Schutz vor fibrotischen 
Organveränderungen spricht. Im experimentalen Teil dieser Dissertation wurde geprüft, 1) ob 
das peroxisomale Kompartiment und die dazugehörige Genexpression bei IPF verändert ist, 
2) ob die Herrunterregulierung der peroxisomalen Biogenese und des peroxisomalen 
Stoffwechsels die Sekretion extrazellulärer Matrixproteine und inflammatorische Mediatoren 
steigert und 3) ob proinflammatorische und profibrotische Zytokine die Anzahl Peroxisomen 
und deren Stoffwechsel beeinflussen. Außerdem wurden die molekularen Mechanismen, die 
zur Veränderungen des peroxisomalen Kompartiments führen, untersucht. Zusätzlich wurde 
ein Bleomycin-induziertes Lungenfibrose-Mausmodell benutzt, um die peroxisomale 
Biogenese sowie Proteine des antioxidativen Stoffwechsels des Lipidmetabolismus zu 
verschiedenen Zeitpunkten nach der  Bleomycinbehandlung zu analysieren. Weiterhin wurden 
die Mechanismen und die spezifische Beteiligung peroxisomaler Proteine bei der  TGF- 
induzierten Produktion extrazellulärer Matrixkomponenten untersucht. Zuletzt wurde der 
Effekt von TGF-1 auf das peroxisomale Kompartment in TRII-, und SMAD3-
Knockoutmäusen, sowie in transgenen TR-I überexprimierenden produzierenden Mäusen 
(TRICA), beobachtet. In dieser Dissertation wurden das peroxisomale Kompartment und 
peroxisomale Stoffwechselproteine parallel zu zelltyp-spezifischen Markern in 
Paraffinschnitten von verschiedenen Lungengewebsproben von gesunden Kontrollen und IPF 
Patienten analysiert. Zusätzlich wurden Primärkulturen von Lungenfibroblasten von 
Kontrollen und IPF Patienten benutzt, um sie morphologisch, biochemisch und 
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molekularbiologisch auf peroxisomale Veränderungen zu untersuchen. Weiterhin wurden 
Primärkulturen von gesunden und IPF Patienten mit TGF-TNF-, IL und PEX13 
siRNA behandelt, um den Einfluss von Peroxisomen auf die molekulare Pathogenese der IPF 
besser zu verstehen. Um die in vitro Ergebnisse zu bestätigen, wurden die Biogenese und der 
Stoffwechsel in der Peroxisomen in situ in Wildtyp Mäusen mit Bleomycin induzierten 
Lungenfibrose im Vergleich zu TGF-beta Rezeptor II Knockoutmäuse (TRII) untersucht. 
Beim Vergleich peroxisomen-assoziierter Protein-und Genexpression in Lungengewebe und 
isolierten Fibroblasten gesunder Kontrollen und IPF Patienten fiel auf dass die Biogenese und 
der Stoffwechsel der Peroxisomen signifikant herunterreguliert wurden (z.B. PEX13p, 
Katalase, ABCD3 und Acyl-CoA-Oxidase 1). Ferner wurde die Bleomycin-induzierte 
Herunterregulierung der Peroxisomen in TRII Knockoutmäusen aufgehoben, was auf eine 
wichtige Rolle von TGF-beta auf die Regulierung der Peroxisomen hinweist. Zusätzlich 
wurde nach Behandlung mit den profibrotischen Faktoren, TGF-β1 oder TNF-α in IPF 
Fibroblasten eine Herunterregulierung der Peroxisomen durch den AP-1 Signalweg 
beobachtet. Deswegen wurden die Mechanismen, duch die eine Verringerung der 
Peroxsiomen zu vermehrten Fibrose beitragen, im Detail untersucht. Eine direkte 
Herunterregulierung der PEX13 mRNA via RNAi 1) induzierte die Aktivierung  des Smad-
abhängigen TGF-β Signalwegs und wurde begleitet von einer gesteigerten ROS-Produktion, 
2) resultierte in der Freisetzung von Zytokinen (z.B. IL-6, TGF-β1) und der übermäßigen 
Produktion von Kollagen I und III.  Im Gegensatz dazu führte eine Behandlung mit 
Ciprofibrat oder WY14643, beides PPAR-α-Aktivatoren, zu einer Proliferation der 
Peroxisomen und der reduzierten TGF-β-induzierten Myofibroblastendifferentiation, sowie zu 
verringerten Kollagenmengen in IPF-Zellen. 
Zusammenfassend konnte in dieser Dissertation nachgewiesen werden, dass Peroxisomen bei 
der ideopathischen Lungenfibrose stark verändert und beeinträchtigt sind, und dieser Prozess 
durch TGF-1 und dem Einfluss von proinflammatorischen Zytokinen (TNF- und IL-6) 
mittels der AP-1 Signaltransduktion ausgelöst wird.  TGF- reguliert Peroxisomen mittels 
des Smad-abhängigen Signalwegs herunter, was in einer verminderten Fähigkeit, zu 
intrazellulären ROS-Abwehr mündet. Zusätzlich werden proinflammatorische Mediatoren 
(Eicosanoide) nicht mehr abgebaut, was in einen Teufelskreis mündet und zur 
Verschlechterung der ideopathischen Lungenfibrose führt. Somit scheinen TGF- and    
TNF- zur Exazerbation der klinischen Symptome und der verstärkten Fibrose von IPF 
Patienten durch die Herunterregulierung der peroxisomalen Biogenese und des peroxisomalen 
Stoffwechsels (z.B. PEX13, ACOX1) beizutragen. 
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